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Featured Application: The specific application of this review article is for the advancement of
commercially translatable technologies in the field of whole organ engineering.
Abstract: End-stage organ failure remains a leading cause of morbidity and mortality across the globe.
The only curative treatment option currently available for patients diagnosed with end-stage organ
failure is organ transplantation. However, due to a critical shortage of organs, only a fraction of
these patients are able to receive a viable organ transplantation. Those patients fortunate enough
to receive a transplant must then be subjected to a lifelong regimen of immunosuppressant drugs.
The concept of whole organ engineering offers a promising alternative to organ transplantation
that overcomes these limitations. Organ engineering is a discipline that merges developmental
biology, anatomy, physiology, and cellular interactions with enabling technologies such as advanced
biomaterials and biofabrication to create bioartificial organs that recapitulate native organs in vivo.
There have been numerous developments in bioengineering of whole organs over the past two
decades. Key technological advancements include (1) methods of whole organ decellularization
and recellularization, (2) three-dimensional bioprinting, (3) advanced stem cell technologies,
and (4) the ability to genetically modify tissues and cells. These advancements give hope that
organ engineering will become a commercial reality in the next decade. In this review article,
we describe the foundational principles of whole organ engineering, discuss key technological
advances, and provide an overview of current limitations and future directions.
Keywords: whole organ engineering; extracellular matrix; biologic scaffolds; constructive remodeling;
tissue remodeling; wound healing; decellularization; genetic engineering; tissue engineering;
regenerative medicine; stem cells
1. Introduction
End-stage organ failure affects millions of people every year in the United States alone.
Heart disease is particularly burdensome to the healthcare system, having been the leading cause of
death in the US for the past decade, with heart failure contributing to 1 in 8 deaths in 2017 according
to the Center for Disease Control [1]. Chronic kidney disease had a prevalence of 15% in the US,
or approximately 37 million people, in 2019, with over 661,000 of these individuals having progressed
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to end-stage renal disease (ESRD) [2,3]. While various therapies can mitigate the progression of
organ disease, autologous organ transplantation is currently the gold standard for end-stage organ
failure [4]. Kidney transplants have been shown to improve patient survival when compared to
dialysis, and transplants of the liver, heart, and lungs are life-saving [4]. However, while organ
transplantation is an immensely beneficial technology, it is significantly limited by the shortage of
transplantable organs. From 1991 to 2019, the number of individuals on the waiting list for organ
transplants has rapidly increased from around 23,000 to over 112,000, while the numbers of organ
donors and organ transplant operations performed have increased relatively marginally from 7000 to
19,000 and 15,000 to 39,000, respectively [5]. Figure 1 graphically represents the disparity resulting
from different growth rates of individuals in need of organs and number of transplants performed.
This large difference in organ supply and demand contributes to the deaths of 20 people every day who
are on a transplant waitlist [5]. In addition to the disparity between number of donors and number
of patients on the waitlist, the shortage of transplantable organs is exacerbated by the fact that on
average, only 0.3% of individuals die in a way that makes their organs viable for transplantation,
as deaths caused by old age, disease, or severe physical trauma can compromise the functionality
of organs [5]. International organ transplantation data illustrates a similar trend globally. A report
in 2017 by the Global Observatory on Donation and Transplantation found that data comprising
82 member states, whose data was representative of approximately 75% of the global population,
showed that the 139,024 organ transplantations performed that year barely accommodated 10% of
the global need [6].
Figure 1. In the US: (a) Most needed organs on the transplant waitlist and their respective percentages
in 2020 as of March, (b) number of individuals on the waitlist and the number of transplantations
performed from 1991 to 2019, and (c) number of transplants performed in 2019 organized by organ.
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Even if a viable organ is successfully excised, patient-donor compatibility concerns can prevent
transplantation from occurring [7]. A blood type match is necessary for all organs, but other
congruencies such as body size as well as geographical location of donor and patient can affect
the viability of some organs, limiting the potential for transplantation [7]. Furthermore, individuals
who are fortunate enough to receive a life-saving organ transplant must remain on immunosuppressant
drugs indefinitely to prevent organ rejection via an immune response [8]. Rejection occurs because
transplanted organs are attacked by the patient’s immune system due to the patient’s immune
cells’ identifying the antigens present on the surface of the donated organ cells as foreign [8].
Immunosuppressant drugs decrease the likelihood of transplant rejection; however, they also put
the transplant recipient at risk. Patients become more susceptible to infections at the site of surgery
while the wounds have yet to heal, and for the rest of their lives, they are more susceptible to bacterial
pathogens and viruses [9]. Due to a shortage of organs available, limitations of autologous organ
transplants, and an increase in the population of individuals that require organ transplants, there
remains an unmet clinical need for novel therapies to treat patients with end-stage organ failure.
In this review, we discuss the recent advancements in the field of tissue engineering, specifically using
the extracellular matrix (ECM) to create naturally derived bioengineered organs, which may be used
as an alternative to autologous organ transplantation.
2. Review Methodology
2.1. Literature Search
A short list of field leaders in whole organ engineering was compiled based on the authors
with the highest number of citations reported in Google Scholar. This list was developed by using
the search query “(organ type) whole organ engineering” in Google Scholar, where the organ types
included heart, kidney, bladder, lung, liver, gastrointestinal, skin, and pancreas. The search results
were filtered for only scientific articles and the authors with the most citations across multiple articles
for a specific organ type were considered leaders in their respective field. Journal articles and reviews
by these various field leaders were found using Google Scholar, PubMed, Web of Science, and various
other peer-reviewed journal databases and search engines using the author name and “whole organ
engineering” as the search queries and categorized based on their topic, subfield, and relevance.
Additional articles found during these searches that cited or were cited by the field leaders as well
as related articles with high citation numbers but not written by field leaders were also sorted into
the aforementioned categories. All of the articles used in this review were also analyzed in depth to
determine if they were part of the field of whole organ engineering. This determination was made
based on if the article described a technique for partially or completely reconstructing a whole organ
using tissue-derived materials and/or cells for use in organ repair and transplantation, which is what
constitutes the field of whole organ engineering. The organization of the various literature in this search
formed the structure of the review that is further outlined in this section.
2.2. History of Whole Organ Engineering
An author search using the list of field leaders was conducted using PubMed to determine
the earliest articles by these authors that were both in the field of whole organ engineering and had a
significant impact on the field. Using the search query of author name and “whole organ engineering”,
the search results were sorted by increasing publishing year, and non-review articles with more than
50 citations were analyzed to determine if they were part of the whole organ engineering field using
the aforementioned method in Section 2.1. These high-impact papers were organized in chronological
order by their publishing date to construct a timeline of the whole organ engineering, starting from
the oldest relevant papers in the field to the late 2000’s. The first section features the birth of the field
and foundational technologies of whole organ engineering while the latter sections go into more
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detail about the foundational technologies mentioned and their lasting impact on the field of whole
organ engineering.
2.3. Approaches to Engineering Whole Organs
During the literature search process mentioned in Section 2.1, publications that had methodologies
in common were put in categories. For reviews that cited a number of research reports utilizing a
specific methodology, the reports utilizing those methods were also categorized. Once these papers
were sorted, the most relevant approaches, determined by the total number of citations of the research
reports that fell into each category, became the basis of Section 4: Approaches to Engineering Whole
Organs. The first succeeding section talks about high-level categorization of approaches and the latter
sections go into the most relevant approaches in the field of whole organ engineering that fall into
these high-level categories.
2.4. Recent Developments and Accomplishments
The field of whole organ engineering is quite broad as it encompasses a number of different
sub-fields representing whole organ engineering for specific organs and organ systems. As mentioned
previously in Section 2.1, the literature search regarding the current state-of-the-art in whole organ
engineering was broken up into the following categories for each organ or organ system: heart, liver,
kidney, lungs, pancreas, bladder, skin, and gastrointestinal. Articles in these various subfields found
during the literature search that were published in 2013 or later were organized by their relevance
in the field. This relevance was roughly calculated as the number of citations divided by the number
of years since publishing. Obviously, an article published 5 years ago will have more citations
than an article published last year even if they are similar in their novelty and importance. Using
this relevance score, approximately 3–7 articles in each subfield with the highest relevance are discussed
in chronological order by publishing date in each of the subsections of Section 5: Recent Development
and Accpomplishments, which consist of the aforementioned organ subfields.
Table 1, summarizing the leading publications in the field for each of the last ten years, was put
together using the Web of Science™ search tool from Clarivate Analytics™. The basic search tool
was used with the search terms “whole organ engineering” and “tissue engineering” for topic
and the publication dates were restricted to 2010–2020. The search results were put in order based
on descending number of citations and then the results were categorized by their publication year,
starting with 2010 and ending with 2020. The paper listed for each year with the greatest number
of citations that was not a review was analyzed to determine if it was encompassed by the field of
whole organ engineering. If it was determined to not be in the field of whole organ engineering,
the article with the next greatest number of citations was analyzed. This continued until an article
was determined to be relevant to the field of whole organ engineering and was chosen for the table.
This was repeated for each individual year between 2010 and 2020 until a complete list of the leading
whole organ engineering papers from every year was completed. Each paper was analyzed in depth to
produce a summary and determine the paper’s impact on the field of whole organ engineering.
2.5. Supporting Technological Advancements
A number of publications found during the literature search, both research reports and review
articles, mentioned supporting technologies that contributed to the success of their approach.
These papers were categorized based on the supporting technologies that they mentioned
and the supporting technologies that were most relevant, which had the greatest number of citations
across papers that described it and formed the basis of Section 6: Supporting Technological Advancements.
2.6. Major Challenges and Barriers to Market
Similar to the supporting technological advances section, a number of publications found during
the literature search, both research reports and review articles, mentioned the major challenges
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and obstacles that needed to be overcome before their approach could become marketable or clinically
viable. These papers were categorized based on the challenges and obstacles that they mentioned
and the challenge/barrier categories that were most relevant, which contained the greatest number of
papers, and formed the basis of Section 7: Major Challenges and Barriers to Market.
In addition, as engineered whole organs intrinsically fall under the purview of government bodies
in charge of regulating medical devices, online resources and databases provided by the Food and Drug
Administration (FDA) were used to examine the regulations that whole organ engineering would need
to adhere to. For information regarding regulations in the US, documents provided by the federal
government such as the Code of Federal Regulations provided more information than peer-reviewed
articles, resulting in online federal resources being cited in lieu of such articles.
3. History of Whole Organ Engineering
3.1. Origin and Foundational Technologies
The concept of tissue engineering as a field came into being in the late 1980s, both largely
established and popularized as a distinct field of research by Joseph Vacanti and Robert Langer from
the former’s research article describing the use of polymer networks as cellular scaffolds and their
combined review article outlining the scientific basis and future directions of the novel field [10,11].
Tissue engineering was primarily established to develop technology to overcome the limits of organ
transplantation, with whole organ engineering being a recent development in the field that has shown
the potential to do so [12]. The fundamental concept of tissue engineering is to utilize a biocompatible
material to form a scaffold onto which cells can adhere to and grow on in order to form tissue.
The term “biomaterial” encompasses a vast array of materials from glass to hydrogels, with the best
biomaterial for engineering a tissue being whichever best mimics the tissue type. For example,
porous tantalum metallic scaffolds are suitable for engineering bone tissue due to their mechanical
strength [13]. In comparison, polymeric biomaterials have been used to develop soft-tissue organs,
which are particularly relevant for patients with end-stage organ failure. These biomaterials have
been used in a range of tissue engineering applications due to their material chemistry allowing
for versatility in fabrication methods [13,14]. Synthetic polymers, such as poly(glycolic acid) (PGA),
poly(lactic acid) (PLA), and poly(lactic acid-co-glycolic acid) (PLGA), are the most well-studied
and commonly used synthetic biomaterials in tissue engineering due to their in vivo degradability
by hydrolysis and their biocompatibility [15]. However, while synthetic polymers can be formed
into desirable scaffold structures, they are inadequate for engineering functional tissue because their
lack of cell adhesion sites reduces their ability to direct cell activity [16–18]. Natural polymers are
another category of polymeric biomaterials that are often used for engineering soft tissue. Alginate is
a natural polymer widely used in tissue engineering due to its abundance, gelation characteristics,
hydrophilicity, and physical similarities to native ECM [19–21] . However, alginate does not have
cell-binding side groups, making it difficult for cells to adhere to it, and has been found to limit cell
migration and proliferation [22]. As the goal of whole organ engineering is to direct cellular activity to
form tissue and organ constructs, the native biomaterial scaffolding of the ECM seems best suited for
tissue and organ engineering purposes.
Some of the most significant early research showing the feasibility of tissue engineering
was performed by Joseph P. Vacanti in 1988, where he showed the ability of biocompatible synthetic
polymers to act as scaffold material for cells to be seeded onto [12]. Vacanti also demonstrated
the value of ECM proteins by coating the polymers with collagen and fibronectin to increase cell
adhesion [12]. Additionally, Vacanti identified limitations of tissue engineering research that would
need to be addressed to engineer larger scale tissue, such as tissue size being restricted by the distance
gas and nutrients can diffuse. Vacanti and Langer helped to further establish tissue engineering as a
distinct field with their review article in 1993 by presenting research that used biomaterial scaffolds
as cell adhesion substrates for various cell types of each germ layer, such as nerve bridges composed
Appl. Sci. 2020, 10, 4277 6 of 42
of polymers laden with Schwann cells [10]. In 1997, Eschenhagen et al. utilized embryonic chick
cardiomyocytes and a collagen gel to generate one of the first contractile engineered cardiac tissues,
demonstrating the viability of tissue engineering to be applied to cardiac regenerative medicine [23].
In 2000, Fink et al., developed a bioreactor to stimulate cardiac tissue to produce more mature tissue,
with bioreactors having since become a crucial component of many tissue engineering approaches [24].
Figure 2 summarizes notable discoveries over the last four decades that have greatly contributed to
whole organ engineering.
Figure 2. Timeline of significant discoveries that have contributed to and advanced the field of whole
organ engineering.
3.2. Extracellular Matrix
In Langer and Vacanti’s 1993 review publication, they identified research that fell under
the umbrella of the new field of tissue engineering [10]. Several of these early tissue engineering
works incorporated ECM components by coating synthetic scaffolds with ECM proteins [25]. In 1992,
Mooney et al. performed experiments to assess what ECM proteins and what configurations of
those proteins could dictate hepatocyte behavior, specifically whether the cells would proliferate or
differentiate [25]. They found that rather than a specific protein or scaffold geometry, it was the ECM
density that determined hepatocyte fate by modulating cell shape. Other work has shown ECM-derived
scaffolds to be capable of directing cell adhesion and tissue growth according to the scaffold
orientation [26,27]. Badylak and colleagues demonstrated the repair capacity of engineered ECM
scaffolds in their 1999 publication outlining their studies on the effects of using porcine small intestinal
submucosa (SIS) ECM scaffolds as grafts for goat anterior cruciate ligament injuries [27]. The implanted
SIS graft underwent significant remodeling by the host and thus notably increased in strength to
have similar failure force as a patellar tendon autograft implanted in the same goat, with histology
revealing no difference in inflammatory cell behavior in the two grafts [27]. Similar remodeling
and regenerative mechanisms driven by ECM scaffolds have been observed in animal heart models
as well [28]. van Amerongen et al. implanted type I collagen scaffolds into injured left ventricles of
mice, which were degraded by matrix metalloproteinases and replaced by vascularized ECM [28].
The ECM’s capacity for cell adhesion and ability to direct cell behavior and integrate with host
tissue after implantation, as it did in these studies, have caused it to be one of the foremost scaffold
biomaterials used in tissue engineering.
The ECM is a complex and dynamic composite network of biopolymers laden with bioactive
compounds like growth factors, and is responsible for providing tissue with its structural properties
as well as directing cellular activity [29,30]. The main components of the ECM are collagens, elastin,
proteoglycans, hyaluronic acid, laminin, and fibronectin. There are at least 16 types of collagen,
the most abundant being collagen type I, II, and III, which are interstitial collagens that bundle
together to form fibrils with high tensile strength, type IV which forms X-shaped units that connect
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to form a fibrous network and is abundant in the basement membrane, and type VI which plays a
role in connecting interstitial collagen to cells and aids in cell adhesion to the ECM [30,31]. Elastin is a
protein that is highly elastic, with a higher amount of elastin in tissue resulting in greater mechanical
compliance [30]. Proteoglycans are proteins with several glycosaminoglycan (GAG) side chains
and are highly hydrophilic, allowing tissue to retain water [30]. Hyaluronic acid (HA) is a GAG that
is not covalently attached to a protein, distinguishing it from proteoglycans, though HA does share
proteoglycans’ hydrophilicity and tissue hydrating role [30]. Laminin, which has 15 isoforms at the time
this article was written, is an adhesion protein that is plentiful in the basal lamina, binding to other
ECM molecules such as collagen and other laminins [30]. Fibronectin is another adhesion protein that
contains binding domains for collagens, integrins, and heparin sulfate [30]. These biomolecules form
the composite network of the ECM to provide a substrate, which directs how cells grow and interact
with one another, with changes in the ECM structure changing how cells within it interact. One way
in which changes in the ECM affect cell behavior is in the formation of new tissue. ECM growth
and remodeling is how tissue is formed during embryogenesis, with different tissue ECM’s serving
as microenvironments that can direct cell differentiation into various cell lineages and induce changes
in cell shape that promote certain cell activity [32–34]. ECM remodeling also plays a role in tissue
regeneration, with differences between human adult and fetal ECM composition playing a large
role in directing tissue remodeling to enable fetal cutaneous wounds to heal without scars [32–34].
Because of the ECM’s well-documented roles in the development and maintenance of tissue through
both structural and physiological activity, ECM molecules have become the foundation of whole
organ engineering.
3.3. Growing Human Tissue In Vivo
Cao and Vacanti et al., published results of a tissue engineering approach for engineering cartilage
tissue in the shape of an ear on the back of mice that would become known as the “Vacanti mouse”.
A scaffold comprising PGA, a material often used in surgical meshes, was formed into the shape of
an ear using a plaster mold cast from an alginate construct of a 3 year old’s ear [35]. The PGA ear
scaffolds were then placed in tissue culture dishes and seeded with a chondrocyte cell suspension
derived from bovine calf cartilage [35]. Athymic mice had one chondrocyte-laden scaffold each placed
in a subcutaneous pocket on their backs, with half the mice in the experimental group receiving
an external stent in the shape of the ear and the other half receiving no stent [35]. Twelve weeks
post-implantation, the scaffolds were removed, with histological analysis revealing that the stented
implants had maintained the shape of the original mold and maintained shape during the last eight
weeks of implantation after the stent was removed, while the unstented implants shrank and became
distorted. Both groups had new cartilage that was synthesized by the chondrocytes [35].
3.4. Autologous Engineered Tissues for Organ Resuscitation
In 2006, Atala et al., published their results from a study after implanting engineered bladders
in human patients with end-stage bladder disease from 1999 to 2018, expanding upon previous animal
studies that demonstrated the feasibility of implanting de novo bladder tissue in dogs [36]. Patient cells
from bladder biopsy samples were expanded into muscle and urothelial cell cultures and then seeded
on either a collagen matrix derived from decellularized bladder submucosa or a composite bioscaffold
composed of collagen and PGA, with some scaffolds of each type being covered in an omental wrap [37].
The seeded scaffolds were incubated for 3 or 4 days before implantation, wherein the engineered
bladder was anastomosed to the native bladder with sutures and fibrin glue [37]. Postoperative
analysis was done for up to five years to assess maximum capacity pressure, leakage, and histology
of tissue samples. These assessments found that the composite bioscaffold wrapped in omentum
had the best result in improving patients’ urinary continence and bladder compliance and capacity,
which was concluded to be because the PGA provided greater structural durability than collagen alone,
and the omental wrap enhanced vascularization of the implants [37]. Though an entire organ was not
Appl. Sci. 2020, 10, 4277 8 of 42
engineered ex vivo, the engineered bladder tissue was structurally and physiologically interchangeable
with any segment of the rest of the bladder and was able to regenerate function of failing organs
and improve quality of life for patients.
3.5. First Engineered Beating Heart
The first instance of whole organ engineering was in a heart model via the perfusion
decellularization and then recellularization of a whole rat heart by Ott et al. in 2008 [38]. Ott utilized a
modified Langendorff heart perfusion apparatus, originally developed by Oscar Langendorff in 1895,
to perfuse cadaveric rat hearts with different detergent solutions [38]. The decellularized hearts
maintained their ECM architecture, vascular patency, and valve geometry. Decellularized hearts
were recellularized with neonatal cardiac cells or aortic endothelial cells via intramural injection
and perfusion respectively, and maintained in a bioreactor, demonstrating electrical and mechanical
activity and genetic expression of mature cardiac tissue 8 days after seeding [38]. Maintaining native
ECM structure to generate a contractile whole heart with mature, functional cells further substantiated
the vital role that the structure and composition of the ECM plays in tissue regeneration. As the first
decellularized whole-organ construct, Ott’s work opened up a new area of tissue engineering,
with the techniques he developed laying the foundation for whole heart engineering through
de-cell/re-cell technology.
3.6. Early Success in Animal Studies for Liver Engineering
The key factor in the liver’s distinctive regenerative ability is its unique ECM, which allows
for tissue growth and remodeling in a manner that re-establishes the tissue composition of healthy,
mature liver tissue after injury [39]. Because of this, utilizing ECM-derived bioscaffolds is crucial
for the successful engineering of liver tissue. Similar to the previously mentioned first instance
of whole heart engineering, the first engineered whole liver was developed through leveraging
native liver ECM architecture via de-cell/re-cell methods. In 2009, Uygun et al. adapted Ott et al.’s
heart de-cell/re-cell method for the decellularization and recellularization protocols for rat livers [40].
After decellularization, histological analysis found that >97% of DNA was removed and dye perfusion
revealed the decellularized vascular network to be intact, while perfusion recellularization successfully
seeded rat hepatocytes onto the vasculature, from which they migrated into the tissue and populated
the liver construct [40]. Immunostaining of the liver revealed the cells to be producing hepatic enzymes
and proteins at levels similar to that of functional livers. Furthermore, Uygun assessed early graft
function of the recellularized livers via auxiliary transplantation in rats and ex vivo whole blood
perfusion, finding hepatic function and cellular function preserved with minimal signs of ischemic
damage [40]. Uygun et al.’s work further established whole organ engineering’s viability as a substitute
to transplantation by demonstrating the ability of an entirely engineered whole organ to be viable
and functional after implantation.
3.7. Academic and Industry Pioneers
Many leaders in the field of whole organ engineering have already been mentioned in this review.
Dr. Harald C. Ott, MD, is a pioneer in the field of whole organ decellularization and recellularization,
with his work with the heart model being the first engineered whole organ [38]. Dr. Stephen F.
Badylak, DVM, PhD, MD is a leader in regenerative medicine research with a focus on the importance
of the ECM microenvironment in engineering functional tissue, including through whole organ
engineering. Dr. Basak E. Uygun, PhD is an expert in liver decellularization, having been the first
to adapt Ott’s decellularization for the liver and having been the corresponding author on many
recent liver engineering techniques that utilize ECM as a bioscaffold [41,42]. Dr. Anthony Atala,
MD, was responsible for one of the earliest demonstrations of engineered organs being able to revive
failing organ functionality by implanting engineered bladders in human patients, and has since
performed research that has shown him and his group to be experts and pioneers in organ engineering
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and regenerative medicine, especially in urinary organ engineering [37]. Dr. Alejandro Soto-Gutierrez,
MD, PhD, has done extensive work in whole liver engineering and particularly in using pluripotent
stem cells to revive hepatic function of liver scaffolds sourced from cadavers [43]. In addition to
the leaders in academia, there are many companies, often founded on the basis of technology developed
through academia, that have made great strides in both research and endeavors to commercialize
engineered organs and tissue. Miromatrix is developing engineered whole liver and kidney products
derived from de-cell/re-cell technology, helping to lay the groundwork for the commercialization
of engineered organs [44]. Tissue Regeneration Systems is using three-dimensional (3D)-printed
scaffolds to generate bone grafts and implants for skeletal reconstruction, leveraging the ability of
engineered organ constructs to be customized based on patients’ needs [45]. Rokit Healthcare utilizes
bioprinting technology to generate soft tissue constructs, aiming to generate patient-compatible grafts
and organs [46]. Combined, these leaders in academia and industry are laying the foundation for
greater development and future commercialization of whole organ technologies that could eliminate
the disparity between the number of transplantable organs available and the individuals in need
of transplants.
4. Approaches to Engineering Whole Organs
4.1. High-Level Strategies
There are two major approaches to whole organ engineering: (1) top-down construction
and (2) bottom-up construction (Figure 3). The concept of top-down engineering is to develop
scaffolds that direct cells to form functional tissues. Macroscopic, or even whole organ scaffolds, are
seeded with one or many cell types, where a combination of scaffold remodeling and self-assembly leads
to the formation of a complex 3D tissue or whole organ [47–49]. In contrast, bottom-up engineering
utilizes the smallest component elements of tissue, such as collagen molecules, as building blocks
and combines them to assemble a larger construct [50–55]. Similar to erecting a building by adding one
brick at a time, bottom-up engineering methods are designed to control and organize the interaction of
cells with each other and their surroundings. Using stem cell engineering, it is possible to utilize a
single building block, human pluripotent stem cells (hPSCs), to engineer constructs such as organoids,
and organ-specific functional tissue through a bottom-up approach [56].
Figure 3. Comparison of top-down and bottom-up whole organ engineering strategies.
The most complete top-down methods use whole organs from donor or cadaveric sources that
are decellularized and then re-seeded with autologous somatic cells, induced pluripotent stem cells
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(iPSCs), or adult stem cells [43,48,57]. Using the native matrix composition and complex architecture
to regenerate functional whole organs has distinct advantages over other whole organ regeneration
methods and is the closest to becoming a clinically viable substitution for organ transplantation. Despite
these advantages, several barriers to clinical translation of this approach, such as efficient methods
of maturing cells seeded on decellularized organs as well as proliferating cells to physiologically
viable numbers for recapitulating whole organ structure and function, still need to be overcome [56].
Bottom-up approaches require fabrication methods that can replicate the bulk structure of organs along
with their complex internal geometries. A bottom-up method that has been widely used due to its ability
to generate complex constructs is additive manufacturing, or 3D printing [51]. Three-dimensional (3D)
bioprinting is useful in bottom-up whole organ engineering because organ structure can be replicated
using highly accurate models generated from imaging technology like magnetic resonance imaging
(MRIs) and can print constructs with internal tubular networks resembling vasculature ranging from
arterial to capillary diameters [58]. Additionally, the bioinks used in 3D bioprinting can be derived
from native ECM molecules, such that printed organ constructs have an internal microenvironment
conducive to cell adhesion and proliferation [51,58,59]. Bioprinted organ structures have demonstrated
the ability to replicate specific organ functions. However, increasing the structural and physiological
complexity of organ constructs to be able to produce multiple organ functions in a single engineered
organ remains a challenge.
A significant barrier impeding the creation of whole organs is developing an organ engineering
approach that incorporates functional angiogenesis, lymphangiogenesis, and neurogenesis within a
single organ or organ system [60]. All of these components must be present in an engineered whole
organ, but no one has successfully accomplished this yet.
4.2. Building Organs from Cadaveric Organs (De-Cell/Re-Cell)
While the shortage of donated organs is the primary reason why some individuals can remain on
a transplant waitlist for years, compatibility between donor and recipient is a concern as well. Blood
type and body size are the most apparent limiting factors [7]. Even when all other compatibility factors
are satisfied, the fact that the DNA of the donated organ’s cells are different from the recipient’s DNA
means there is risk of an immune response and organ rejection. However, top-down organ engineering
methods can be used to overcome these limits. Cadaveric and potentially even animal organs
(e.g., porcine) can be engineered to have the donor’s cellular material removed while retaining the ECM
structure and biochemical properties, then repopulated to house non-immunogenic cells. This not
only removes concerns of blood type but also eliminates the concern of the organ recipient’s immune
system recognizing and attacking the donor’s cells in the organ [47,61–64]. Removing the native
cells, or decellularization, commonly involves perfusing the vasculature of an organ with surfactant
and enzyme solutions to kill cells via lysis, then rinsing the vasculature with a saline solution which is
often paired with mechanical stimulation to remove cells embedded in tissue [47,61–64]. This process can
produce an organ construct with the structural properties and biochemical markers of the native organ
while removing native DNA, and thus has the potential to mitigate the immune response to cadaveric
human and even animal organs. Repopulating the acellular cadaveric construct, or recellularization,
involves perfusing the vasculature of the organ with a cell solution and maintaining the construct
in a bioreactor to promote cell adhesion and proliferation [40,62,65–67]. The decellularization will
have removed cells but left the ECM with its structural and biochemical properties, maintaining
a microenvironment conducive to cell adhesion and growth. If the cells used are sourced from
the patient or from cells genetically engineered to be immune-compatible, then the cell-laden organ
construct will not elicit an adaptive immune response upon implantation. Because of the potential for
decellularization/recellularization procedures to remove the immunogenicity of tissue, using cadaveric
human and animal organs as sources for ECM scaffold generation has gained prominence in whole
organ engineering research [56,60,61,68,69].
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ECM and decellularization techniques are a promising method of personalized organ production.
Early work in advancing decellularization approaches focused on maintenance of whole organ function
after decellularization in animal models [70] as well as allogenic clinical studies [71] without seeding
cells in vitro. For example, Ott et al. investigated the mechanical properties and ECM composition
of the rat heart, while Macchiarini et al. characterized clinical factors relevant towards allogeneic
tracheal tissue implantation [37,68]. Such results were limited in scope since they used mechanical
tests to determine decellularized organ function rather than evaluating the regenerative capacity
of the scaffolds. Further investigation by Ott et al., tested the regenerative capacity of a rat heart
in vitro by recellularizing the rat heart with a coronary perfusion bioreactor and then subjecting it
to a periodic electrical stimulus [38]. They found that their approach resulted in the decellularized
heart regaining roughly 2% of the pump function of native adult rat hearts and 25% of the pump
function of a 16-week fetal human heart, and even responded to doses of phenylephrine with increased
contractility as a native heart would [70]. Engineered whole human trachea allografts were analyzed
before and 3 months after implantation, and it was found that physiological function was restored
in the graft and that the grafting procedure resulted in the reversal of airway obstruction [71].
4.3. Building Organs from Synthetic Biomaterials
Synthetic scaffolds and grafts are a tool for structural engineering and development of implantable
organs. In the late 1970s and early 1980s, many researchers and scientists began developing new
approaches to shaping polymers into sophisticated and complex structures, which resembled the needed
architectures of whole organs and tissues. The manufacturing methods resulted in reproducible
and tunable scaffolding materials for the purpose of tissue regeneration. Synthetic polymer scaffolds
have the advantage of possessing high mechanical strength, adjustable porosity and surface area,
reproducible manufacturing, and engineered surface chemistry [14].
The starting scaffolding is the essential foundation for building functional and viable whole organs.
This is because the three-dimensional anatomic orientation must be similar to naturally occurring
scaffolding in order to be successful. With synthetic biomaterials, these key scaffolding characteristics
and attributes can be engineered to the specific application they are being designed for. Standard
synthetic scaffolding designs have typically consisted of surgical meshes, polymer fibers, sponges, foams,
sheets, and various other configurations. Different types of synthetic biomaterial scaffolds, including
microsphere scaffolds, porous scaffolds, hydrogel scaffolds, fibrous scaffolds, polymer-bioceramic
composite scaffolds, and acellular scaffolds, are all used in these various applications [14].
4.4. Building Organs from Biohybrid Materials
Biohybrid materials are materials comprising both biological and non-biological components.
Biohybrid materials have been explored in tissue engineering applications due to certain drawbacks
of tissue scaffolds comprised solely of biological components. For instance, the ECM plays a vital
role in directing native cell activity and ECM-derived proteins have demonstrated the same ability
in engineered constructs [26,27]. However, objects made of only ECM proteins can rapidly degrade
or are not structurally robust enough to replicate the activity of compliant, matrix-dense tissues [72].
Synthetic polymers can be tuned on the molecular level to generate a scaffold with desired bulk
properties to mimic native ECM’s mechanical properties [72]. Pairing the cellularly interactive
ECM proteins with the mechanical and degradation tunability of synthetic polymers can produce
biocompatible scaffolds that can be modified to suit remodeling of different tissue types.
There are four types of commonly used biohybrid materials: (1) interwoven biological
and non-biological fibers, (2) bilayers comprising distinct synthetic and ECM layers, (3) synthetic
scaffolds seeded with cells that synthesize ECM in the scaffold, and (4) composite hydrogels. Interwoven
synthetic and biological fibers are often formed using electrospinning, and electrospun biohybrid
scaffolds have been implemented in engineering vascular grafts [72–75]. Co-spinning synthetic
and biological polymers allows for the production of independent and distinct fibers on the nanoscale,
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though the deposition of the fibers can be difficult to control and produce a random fiber orientation [76].
Fiber diameter can be modulated by controlling speed and charge of material deposition and can be
adjusted to resemble native ECM both in its dimensions and structural properties [75,76]. Electrospun
biohybrid scaffolds can also be designed with an adequately porous structure to allow for high cell
infiltration and migration [75,76].
In biohybrid bilayers, the synthetic and biological components are discrete components that are
combined in layers [72]. Because the two materials are distinct constituents, generally, a biohybrid
bilayer takes advantage of the properties of a primary material and uses a secondary material to
provide support; for example, the primary material may be the synthetic layer to provide mechanical
strength while the secondary biological layer provides key cell interactive cues [72,77]. Some bilayer
materials utilize intact native tissue, such as the pericardium, due to its high ECM protein content,
low cellularity, and mechanical properties, with a synthetic polymer layer surface crosslinked to
the pericardium [78]. Three-dimensional printing is also a suitable bilayer manufacturing technique,
as layer-by-layer fabrication is readily performed with a 3D printer [79].
For biohybrid materials in which the ECM component is produced by cells seeded on a synthetic
polymer scaffold, the successful integration of ECM proteins depends on the ability of the synthetic
component to allow high cell infiltration and promote cellular production of ECM [72]. Because these
materials incorporate cells, decellularization of the material after adequate ECM synthesis is a critical
step [72]. This type of biohybrid material may be particularly suitable for tissue-specific use if the cells
used to fabricate the ECM in the scaffold can be sourced from the tissue site of interest, as the ECM
produced by these cells will have the same composition as the native ECM [72].
Hydrogel blends are formed by combining ECM proteins and synthetic polymers prior to gelling
the two to form a single, composite hydrogel. Polyethylene glycol (PEG) is often incorporated into
biohybrid hydrogels due to its bioinert property, well understood tunable degradation mechanics,
and high solubility in water [80]. Biohybrid functionality can be achieved by modifying PEG monomers
with bioactive molecules or by physically entrapping them while still maintaining the tunability of
its strength and degradation that can be achieved by controlled crosslinking [72,80,81]. In doing so,
biohybrid hydrogels offer a way to incorporate different biomolecules such as ECM proteins into
microenvironments with tunable mechanics to mimic the conditions of native tissue degradation
and remodeling [72,81].
4.5. Three-Dimensional Bioprinting
One of the more remarkable technological achievements and advancements in recent history
is 3D printing [50,82,83]. Ultimately, one of the most impressive feats to arise from 3D printing
has been the ability to print biological materials and then have those scaffolds seeded with living cells,
which is commonly referred to as 3D bioprinting. This approach includes fundamentals from various
fields, including tissue engineering, materials engineering, cellular biology, and advanced robotic
printing [53,84]. Three-dimensional bioprinting is perhaps the most well-known bottom-up approach
to tissue engineering in the public eye. Three-dimensional printing as a technology came about in 1981
when Hideo Kodama published his work on 3D plastic manufacturing using UV-cured photopolymers,
which would later be developed into the 3D printing technique stereolithography by Charles Hull,
which creates a print layer by layer via UV light hardening a solution from which the print is drawn
out of [85,86]. Other 3D printing methods were developed later, including Fused deposition modeling
(FDM), which is used in popular consumer plastic printers, in 1988, selective laser sintering in 1986,
and selective laser melting in 1995 [87,88].
Three-dimensional printing is attractive in whole organ engineering because its ability to generate
custom and complex geometries has the potential to translate well into generating personalized organs
for patients. The technology was first used in medical applications in the early 2000s for printing hard
constructs such as bone implants and prosthetics [89]. Human-scale bone scaffolds have been generated
using selective laser melting or sintering of materials like alloys and bioresorbable polymers [90,91].
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Even more in its infancy than solid construct printing is soft construct printing to replicate soft tissue,
done using inkjet, extrusion, or stereolithography (SLA) printing. Inkjet bioprinting uses electric,
mechanical, or thermal stress to compress the bioink into a droplet as it is extruded [51].
Bioinks used in inkjet bioprinters are often composed of cells encapsulated in solubilized
biopolymers such as collagen and fibrin that gel after extrusion, allowing for more homogeneous
and controllable distribution of cells in an engineered tissue construct than when cells are seeded
onto a scaffold, which can contribute to cell behavior better mimicking native functions [53,59].
Extrusion-based bioprinting utilizes FDM printing technology with a specialized extrusion head,
often a syringe tip, to extrude a bioink comprising a structural solubilized biopolymer solution like
alginate or collagen, a cell solution, or a combination of the two. Extrusion bioprinting can either
use different bioinks as scaffolding and for cell delivery, build the scaffold and extruding cells into
the scaffold, or utilize a composite bioink in which cells are laden within a structural biopolymer
solution [58,92]. Similar to inkjet printing, extrusion printing’s use of cell-laden bioink that is laid
out in predetermined structures results in a more homogeneous and controlled cell distribution
that is conducive to cell proliferation, tissue growth, and the recreation of native cell function [58].
SLA bioprinting is performed largely in the same manner as traditional SLA, using a photocurable
pool of material from which a platform is lowered with a laser curing the material layer-by-layer [93].
Regardless of the 3D printing technique utilized, bioprinting soft tissue constructs is advantageous
because of both the customizability and precision it provides. This precision is highly desirable
in producing vascular networks within tissue constructs, as tissue size is otherwise limited by
the distance which gas and nutrients can diffuse. The bottom-up approach of 3D bioprinting would
allow for this limit to be overcome by generating whole organs with hollow networks built-in so that
the construct is vascularized [51].
4.6. Organoids
Organoids are a tissue engineering technology that seeks to replicate native organ function
in miniature fetal or adult organ-like structures. They have been used for more accurate disease
modelling, toxicology and drug studies due to their greater similarity to native organs than more basic
in vitro cultures, as well as tissue/organ replacement [94,95]. Organoids are also well suited to these
applications as they can be developed from patient-derived cells, improving the accuracy of disease
models or drug studies and mitigating the concern of an immunological response of tissue replacement.
Patient-specific toxicology studies have been demonstrated to be a particularly useful application
of organoids, as native organ physiology can be replicated and tested in vitro if the organoids are
engineered using patient cells [94,96]. Cristobal et al., developed human colon organoids derived
from both healthy and cancerous sections of colon from patients with colorectal cancer [94]. Using
proteomic analysis of the organoids, Cristobal and colleagues were able to identify specific phenotypes
in patients that could dictate their disease progression and ultimate clinical outcome, thus allowing a
personalized treatment to be developed thanks to the organoids [94]. In 2016, Kim and colleagues
demonstrated that organoids formed from pancreatic cells derived from human embryonic stem cells
were capable of performing pancreatic endocrine functions in vitro and in vivo [95]. In vitro glucose
stimulation of the pancreatic organoids induced release of insulin-containing vesicles, and implantation
of the organoids into diabetic mice resulted in a decrease of blood glucose levels and insulin was detected
in the transplant sites [95]. These results demonstrate the ability of organoids to replicate and even
replace organ function, doing so autonomously in response to native physiological cues.
Organoid technology can potentially be utilized to advance whole organ research. Both areas of
tissue engineering are concerned with addressing organ failure and regeneration, and both have
similar challenges. The main technical challenge in the way of organoid development is engineering
an organoid environment that provides the same structural support biochemical cues as the native
environment. As the native ECM is intrinsically designed for such a purpose, utilizing native
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ECM components to engineer the organoid microenvironment is an approach that shows promise
in addressing this challenge.
5. Recent Developments and Accomplishments
5.1. Heart
The quest of engineering a viable and functional whole-heart replacement via whole organ
engineering necessitates the development of various approaches for cellular removal due to the high
density, large mass, and anatomic complexity of the native human heart. Preclinical studies that
utilize perfusion decellularization of rodent hearts have presented encouraging results, but applying
this technique to larger animal models such as porcine and bovine that would translate to clinical use
of this technique are still a challenge [38]. In a 2010 study conducted by Wainwright et al., a porcine
heart was decellularized reproducibly and efficiently using retrograde aortic perfusion with a mixture
of solvents, but reseeding this scaffold efficiently requires further research [97].
Decellularization and recellularization approaches are prevalent in whole heart engineering
due to the heart’s complex geometry and electromechanical functions making the native ECM
architecture difficult to replicate in vitro. Guyette et al., expanded upon Ott et al.’s original whole
heart decellularization work in 2008 according to standardized protocols developed in the Ott lab
to decellularize donated human hearts, and successfully removed over 99% of double-stranded
DNA, as determined by endonuclease perfusion [98]. Micro-computed tomography (CT) scans
found no statistically significant difference in vascular density between cadaveric and decellularized
cardiac matrix, though the decellularized hearts did have lower vascular densities, especially
in the endocardium, showing that the decellularization process preserved vasculature but that
full-depth vascular recruitment is more difficult in a decellularized heart [98]. The decellularized
constructs were repopulated with cardiomyocytes derived from human iPSCs in a custom bioreactor.
Analysis of cell activity revealed glucose consumption and lactate production that suggested metabolic
activity, electrical stimulation produced visible contractions, and histological analysis showed over
90% cell viability, which indicated that coronary perfusion was providing adequate nutrition
and gas exchange [98]. Taylor et al., utilized a porcine model, using de-cell/re-cell procedures
on porcine hearts and then heterotopically implanting them in living pigs to leverage the body’s natural
ability to repopulate the scaffold to a greater extent than if only ex vivo recellularization were used [99].
The heterotopic hearts were rapidly endothelialized by host cells, which could potentially reduce clot
formation after transplantation, which is a concern with the heart transplant process [99]. Using a
decellularization approach to generate whole heart cell scaffolding is promising, but does have its
challenges, as assessed in a study by Sanchez et al., which used the data from 39 heart decellularization
procedures to identify critical troubleshooting points in the process [100].
Bottom-up heart engineering techniques, namely 3D bioprinting, are an alternative avenue of
research for pursuing whole heart engineering without the challenges of de-cell/re-cell approaches [58,92].
Noor et al., developed a novel, personalized bioink fabrication method for extrusion bioprinting thick,
vascularized cardiac tissue [92]. The personalized bioink was composed of thermoresponsive ECM
hydrogel and cardiomyocytes derived from iPSCs, both of which were derived from omental tissue [92].
A sacrificial support material was used for printing, allowing complex geometries to be generated while
the structure maintained its shape; thus, allowing cellularized cardiac patches with built-in vasculature
and miniature hearts to be printed [92]. This technique’s ability to generate vascularized constructs
with complex geometry and its use of cellularized bioink derived from patient omentum, a readily
available cell source, make it a promising approach to whole organ engineering. Another bottom-up
approach to cardiac tissue engineering was published by Lee et al. in 2019 utilizing an improved version
of their freeform reversible embedding of suspended hydrogels (FRESH) printing technique [54,58].
FRESH utilizes an extrusion bioprinter to print into a sacrificial gelatin microparticle coacervate that
supports the extruded bioink as it crosslinks and solidifies and then is removed by melting the support
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at physiological temperatures (37 ◦C), allowing for complex geometries to be printed as one continuous
construct using cell-laden bioinks, then removed from the support material in conditions unharmful
to cells [54]. Lee and colleagues used FRESH and collagen bioink to print a human neonatal-scaled
heart of a MRI-derived heart model, a 1:1 scale human tri-leaflet heart valve that was mechanically
functional in an ex vivo pulsatile perfusion system, a perfusable vascular network with vessels as small
as 100 microns, and a cardiac ventricle printed with an infill of cardiac cell bioink that demonstrated
synchronized contractions along directional action potential propagation [58]. FRESH bioprinting
demonstrates the capability to engineer tissue with properties needed to generate viable cardiac
transplant tissue; however, more work must be done to be able to FRESH print these properties
in a single construct, as the patient-specific geometry, vascularization, and functional cell population
properties were achieved individually in separate constructs.
5.2. Liver
Bioengineering a whole liver has long been clinically appealing because of the liver’s tremendous
ability to regenerate and the therapeutic potential of transplanted livers, which are the current
standard for treating end-stage liver disease. A focus of whole liver engineering has been research
and development of an acellular tissue scaffold engineered from a whole liver, aiming to utilize the native
structure to house parenchymal cells that will revive liver-specific functions. Uygun et al. published
work demonstrating that perfusing rat livers with sodium dodecyl sulfate (SDS) solution followed by
Triton X-100 solution through the hepatic portal vein resulted in the removal of cellular material, namely
DNA, in the livers, while still retaining the native 3D ECM architecture and preserving the vascular
architecture [40]. By recellularizing the acellular architecture with adult rat hepatocytes via their
previously developed seeding protocol, Uygun and colleagues found that the hepatocytes remained
viable for 5 days, with albumin and urea production levels during that time indicating that the cells
were metabolically functional. The engineered livers were then heterotopically transplanted into rats,
which demonstrated that engrafted hepatocytes were able to remain in their original attachment point
and maintain their cellular morphology when exposed to blood flow from the host circulatory system,
despite the resulting shear stress the circulation imparted on the cells. Furthermore, hepatic function
such as secretion of albumin and urea as well as activity levels of CP450 were comparable to those of
in vitro studies, which demonstrated the possibility for an engineered whole liver to function as a liver
transplant in rats [40].
Baptista et al., also developed a bioengineered whole rat liver, in which human hepatic cells
were successfully incorporated. Excised rat livers were perfusion decellularized using a solution of
Triton X-100 mixed with ammonium hydroxide. The acellular liver scaffolds were then recellularized
using human umbilical vein endothelial cells (HUVECs) and human fetal liver cells via perfusion
of the preserved vascular network [63]. These rat livers cellularized with human cells were
cultured in a bioreactor and displayed morphology and function resembling that of native liver
tissue. The fetal liver cells and endothelial progenitor cells used were able to differentiate into
mature endothelial and hepatic-specific cells. In 2015, Ko and colleagues successfully conjugated
anti-endothelial cell antibodies to the inner wall of blood vessels before recellularizing decellularized
porcine livers, demonstrating that this approach could generate functionality within the liver vascular
network [101]. This approach enabled endothelial cells to homogenously attach to both larger blood
vessels as well as capillaries, significantly reducing the extent to which platelet adhesion occurred
once in vitro blood perfusion was performed. After vascularization, the bioengineered porcine
livers were capable of withstanding the shear stress arising from blood flow and successfully avoid
thrombosis after implantation into pigs. In another study by Hussein et al. in 2016, instead of using
anti-endothelial cell antibodies, a heparin-gelatin mixture was incorporated to improve the attachment
efficiency of endothelial cells as well as mitigate thrombus formation [102]. Using this methodology,
bioengineered livers that underwent vascular network reconstruction were also implanted and studied
in porcine models.
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In 2011, Soto-Gutierrez et al., used perfusion with enzymatic and non-SDS detergent solutions
along with mechanical stimulation to decellularize whole rat livers, with analysis of the decellularized
whole liver matrices revealing that in addition to preserving the structure and vasculature of the liver
ECM, their decellularization process maintained ECM composition and presence of growth factors,
which can often be eliminated during decellularization [42]. Soto-Gutierrez and colleagues found
that the decellularized livers maintained about 50% and 40% of the hepatocyte growth factor (HGF)
and basic fibroblast growth factor (bFGF) respectively, contained in native livers [42]. HGF and bFGF
contribute to stimulation of epithelial cell proliferation and migration, angiogenesis, and wound healing
in the liver, which contributed to the >90% cell engraftment efficiency observed after recellularization
with rat hepatocytes, with engrafted cells showing hepatic metabolic activity [43,103,104]. Other liver
decellularization methods have leveraged the native ECM to improve patient-specific cell sourcing
and reendothelialization of vascular networks in engineered whole livers [41,42,105]. Jaramillo et al.
showed that the mechanical and physiological signals of decellularized liver ECM resulted in improved
hepatic differentiation of human iPSCs when compared to the same protocol with Matrigel, improving
prospects for patient-derived iPSCs to be used in patient-specific engineered livers [41]. Improved
reendothelialization of decellularized livers was shown to result from the conjugation of the REDV
cell binding domain of endothelial cells to an elastin-like peptide (ELP) by Devalliere et al. [42].
A different approach to reendothelialization of decellularized whole livers by Mao et al. used porcine
umbilical cord-derived endothelial cells, resulting in maintenance of an intact vascular network after
an extensive 72 h of ex vivo perfusion without thrombus formation, which can easily form when
perfusing an organ for that long [103]. These studies represent successful, ongoing efforts to engineer
functional vasculature within decellularized whole livers in order to recellularize them with functional
hepatocytes and generate clinically applicable engineered livers.
5.3. Kidney
Whole kidney engineering has been performed through both top-down and bottom-up approaches.
As is the case when engineering other whole organs, the use of a decellularized cadaveric kidney
is a widespread approach to top-down kidney engineering [64,106–109]. Standard decellularization
protocol utilizing SDS to remove cellular material is applicable to whole kidneys and is commonly
used [64,106–109]. In 2013, Orlando and colleagues demonstrated the potential for top-down
engineered kidneys to help reduce the disparity between organ supply and waitlisted individuals
by engineering viable renal scaffolds from discarded human kidneys [106]. Kidneys are generally
discarded for anatomical anomalies like atrophy or hardening of the renal vasculature, inflammation,
or cortical necrosis, as well as prolonged ischemic storage [106]. Using SDS perfusion decellularization
protocols, discarded human kidneys were found to maintain their ECM structure, vascular patency,
and biochemical properties [106]. This research demonstrates the potential for whole organ engineering
to lessen the organ recipient/donor disparity using readily available resources. Repopulation of acellular
cadaveric kidney scaffolds has been demonstrated as well [47,110,111]. Ciampi et al., repopulated
decellularized rat kidney constructs with human endothelial cells derived from iPSCs [111]. Endothelial
cell infusion through the renal artery of the rat kidneys led to widespread, homogeneous distribution
of endothelial cells along the inner walls of the vasculature [111]. Transmission and scanning electron
microscopy revealed that fenestration only occurred in the glomerular capillaries, indicating that the rat
ECM scaffold had modulated endothelial cell adhesion and phenotype [111]. These findings suggest that
whole kidney engineering via a top-down approach can maintain kidney macro- and micro-structure
and preserve biochemical properties of renal structures to direct cell adhesion and activity.
Additive manufacturing methods for kidney engineering have been utilized as well, and are
showing promise in being able to replicate the internal architecture of the kidney [112–115]. Ali et al.
published results of a novel ECM-derived, photo-crosslinkable bioink they had developed [112].
The bioink was derived from porcine kidneys that were perfusion decellularized with SDS, Triton-X 100,
and nuclease enzymes, with the acellular ECM scaffold then being solubilized with acid, and the solution
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then methacrylated so that it could be photo-crosslinked using UV light [112]. Constructs were printed
using the kidney-derived bioink with human kidney cells included, with the resulting printed
constructs retaining structural properties of native kidney tissue, and the cells remaining viable over
time and maturing [112]. More recently, Carreno-Galeano et al. utilized the same kidney-derived
bioink to print ECM constructs laden with human kidney cells and implanted them in nude rats [115].
The constructs remained viable for two months, with comparisons of the implant site at the two-month
timepoint to earlier times revealing that new tubular structures formed in the tissue around the implant,
with human kidney cell markers detected in these new structures [115]. Host renal progenitor cell
recruitment was observed in tissue surrounding acellular constructs that were implanted as well [115].
5.4. Lungs
Proper respiratory function is heavily dependent on lung tissue mechanics, due to the need
for an ECM structure that promotes gas exchange and elasticity. Replication of native lung tissue
mechanics has been accomplished via various decellularization approaches. The first experiments
in which a whole bioengineered lung was created using decellularization and recellularization were
published in 2010 by Ott et al. and Peterson et al. [48,116]. Due to the dependence of respiratory
function on the compliance of lung tissue, it is crucial that engineered whole lungs retain the native
lung tissue mechanics as much as possible after decellularization, as the process can damage native
ECM in addition to removing cellular material. Because of this, decellularization protocols must be
developed to be as harmless as possible to lung ECM. Various perfusion methods using detergent
solutions such as SDS, Triton X-100, and CHAPS, as well as enzymatic solutions, have been studied
in various animal and human models to determine effective decellularization methodologies [117–120].
However, decellularization protocols are not well standardized, and the optimal decellularization
method is undefined. Early lung recellularization procedures were done via injection of primary
pulmonary and endothelial cells, and related cell lines, into the trachea and pulmonary artery [48,116].
Restoring the ability of the lungs to perform their most primary function, gas exchange, requires
reconstruction of the microstructures comprising the airways and blood vessels of a recellularized
lung repopulated with epithelial and endothelial cells, respectively. To that end, recellularization
has been approached via supplying endothelial cells and perivascular cells through the pulmonary
artery and the pulmonary vein, while the airway is epithelialized via the bronchial system [48,116–120].
In 2018, Zhou et al., published their results of a large animal study in which they
recellularized acellular porcine lung scaffolds with human airway progenitor cells and HUVECs [117].
The recellularized lung constructs were maintained in a bioreactor for 6 days to allow the seeded cells to
mature. The humanized porcine lungs were then transplanted into pigs and perfused using the host’s
pulmonary circulation for 1 h. It should be noted that the bioengineered lungs displayed reduced
capabilities of gas exchange and mechanical compliance when compared to native lung tissue. Various
groups have developed bioreactors for maintaining recellularized grafts in vitro, in which cellular
differentiation or maturation can be facilitated via steady vascular perfusion and bronchial ventilation.
These bioreactors are intended to mimic the physiological conditions native lung tissue is exposed to
and thus enable cells to create an organ in vitro that resembles the native lung. For recellularization
of acellular lung scaffolds, pulmonary cells are often derived from iPSCs because iPSCs can be
autologously sourced and then expanded to the requisite cell population size needed to repopulate
whole lungs [48,116–120].
Functional endothelialized pulmonary vasculature must be able to maintain a fluid-tight seal
while still permitting the exchange of oxygen and carbon dioxide. Dr. Laura E. Niklason’s group
developed a successful protocol for seeding decellularized lung scaffolds with endothelial cells by
perfusing cells into the lung microvasculature [116]. However, this method was not able to successfully
generate an endothelial layer with barrier functionality and was susceptible to thrombosis. In a 2019
study, Niklason’s group expanded upon their work in Yuan et al., 2019 by incorporating various
small, bioactive molecules into the recellularization of decellularized lungs to determine if this would
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result in improved endothelial function [121]. They found that incorporating 8CPT-2Me-cAMP,
an Epac-selective cyclic adenosine monophosphate analog, into the recellularization process resulted
in superior endothelial barrier function within the recellularized lungs. HUVECs treated with this Epac
agonist demonstrated improved barrier functionality that could be maintained for at least three days,
as opposed to the five-hour-long effect resulting from other molecules Niklason and colleagues tested.
Epac agonist treatment resulted in reorganization of actin structure, as well as an increase in continuity
of the junction proteins VE-cadherin and ZO1. When actin polymerization was prevented, the effects of
the Epac agonist were removed, substantiating a strong actin-mediated effect. In addition, iPSC-derived
endothelial colony forming cells (ECFCs) treated with the Epac agonist displayed an increase in barrier
function that was maintained for >60 h. The iPSC-ECFCs were shown to maintain their phenotype after
being cultured in lung scaffolds for 5 days, as evidenced by their expression of the proteins CD31, eNOS,
vWF, and VE-Cadherin. Niklason and colleagues’ work shows that Epac-selective 8CPT-2Me-cAMP is
a potentially useful tool in improving the functionality of engineered endothelium in bioengineered
whole lungs, which is a vital component of whole lungs [121].
Nichols et al., also utilized decellularization and recellularization of porcine lungs to approach
developing a bioengineered lung on a clinically relevant scale [122]. Using hydrogels laden with
growth factor containing nanoparticles, Nichols and colleagues were able to promote improved cell
adhesion to decellularized whole porcine lungs. These scaffolds were developed into bioengineered
lungs by seeding them with autologous cells and showed vascular perfusion from collateral circulation
after less than 2 weeks post-transplantation. The transplanted lungs could be aerated and contained
a microbiome similar to that of native lung. One pig displayed no symptoms of respiratory issues
when euthanized an entire 2 months after transplant. This work is a considerable advance in the lung
tissue engineering field and demonstrated the viability of tissue-engineered lungs in the realm of
clinical applications.
5.5. Pancreas
The pancreas is a heterogeneous organ that has both exocrine and endocrine functions. The exocrine
function is performed by acinar cells, which secrete enzymes to aid in digestion. In contrast, endocrine
activity is carried out by the islets of Langerhans, which produce hormones to regulate glucose levels
within the blood. Pancreatic tissue transplantation is primarily used for patients with severe cases
of type I diabetes (T1D), which eliminates the insulin-producing beta cells of the pancreas causing
hyperglycemia. Inadequate control of blood glucose levels can lead to significant complications
and may require an islet transplantation to restore beta cell function. However, there are a limited
number of donor pancreata available, which currently makes this strategy unsustainable as a long-term
treatment option for T1D. In addition to organ shortage, islet transplantation is associated with a
significant loss of islets due to poor blood supply reducing the effectiveness of this therapy. Finally,
this allogeneic cell source requires immunosuppression to avoid transplant rejection. To address these
concerns, researchers are evaluating the efficacy of naturally derived acellular scaffolds to generate
novel therapies for treating T1D.
Bioengineering the endocrine pancreas presents several challenges. One of these challenges is to
replicate the islet cell niche, which consists of a unique three-dimensional ECM structure and vasculature
embedded within a cluster of endocrine cells [123]. Top-down whole pancreas engineering methods
have been developed to utilize native pancreatic ECM as a scaffold to support islet cell function [124–128].
Goh et al., used perfusion decellularization to obtain an acellular ECM scaffold from whole mouse
pancreata and characterized both exocrine and endocrine function after reseeding the scaffold with
acinar (AR42J) and mouse beta cells (MIN-6) [124]. Whole pancreata were harvested from Institute
for Cancer Research (ICR) mice perfused through the pancreatic vasculature via the hepatic portal
vein. Detergent-based solutions, 0.5% SDS and 1% Triton X-100, were used in tandem with nucleases
to clear cellular components. Acellular pancreatic scaffolds were subcutaneously implanted into
C57BL/6 mice for 14 days and showed active angiogenesis within the implantation site while limiting
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the immune response, which is critical for islet survival. Upon recellularization with acinar and beta
cells, amylase and C-peptide expression confirmed that these cells localized within their specific
physiological niche. Mirmalek-Sani et al. developed a more clinically translatable approach by utilizing
porcine pancreata to generate ECM scaffolds, which were seeded with human stem cells and porcine
islets [125]. Porcine pancreata were perfused with 1% Triton X-100 and 0.1% ammonium hydroxide
for 24 h then rinsed with phosphate buffered saline for 5 more days until tissues were decellularized.
Porcine scaffolds seeded with human amniotic fluid-derived stem cells grew significantly after 7 days
in culture, confirming cytocompatibility. Additionally, porcine islets that were seeded onto pancreatic
ECM demonstrated an increase in metabolic activity and insulin production between 3 and 7 days.
Peloso et al., decellularized human pancreatic tissues to move toward the development of a bioartificial
endocrine pancreas (BAEP) [126]. The BAEP was generated by decellularizing human pancreata via
perfusion of 1%Triton X-100 and 0.1% ammonium hydroxide for 48 h and washing with PBS for an
additional 5 days. A chorioallantoic membrane (CAM) angiogenic assay showed that pancreatic
ECM triggered neovascularization and did not significantly differ from VEGF, which demonstrates
the angiogenic potential of the ECM. Additionally, human pancreatic ECM showed the ability to direct
immune cell fate by inhibiting naïve CD4+ T-cell proliferation, triggering T-cell apoptosis and pushing
naïve CD4+ T-cells toward T-reg cells. Human islets and endothelial cells cultured on human pancreatic
scaffolds initiated insulin secretion and blood vessel formation, which indicates that the human
ECM could provide an appropriate niche for generating a functional BAEP. Hashemi et al. tested
varying concentrations of detergents and their impact on the decellularization of rat pancreata [127].
Intact vasculature and significant reduction in immunogenic content was optimal using 0.05% SDS
for 6 h for both cannulation of the common bile duct and aorta. Using the same decellularization
protocol, Hashemi et al., showed that acellular rat pancreatic scaffolds were recellularized in vivo
post-implantation with de novo vascularization and the presence of infiltrated beta cells [128]. Overall,
the development of acellular pancreatic scaffolds has shown great promise for supporting the survival
and function of pancreatic islets across species, which could lead to improved outcomes for pancreatic
cell transplantation.
In addition to providing a biocompatible pancreas-like niche, next-generation therapies aim to
address the shortage of donor islets and immune-rejection. Current strategies are exploring the use
of stem cells to mass-produce functional beta cells, which could dramatically reduce or completely
replace the need for donor pancreatic tissues. Pagliuca et al. developed a differentiation protocol
to generate millions of glucose-responsive human beta cells from human pluripotent stem cells
(hPSCs) [129]. This discovery was a major step forward in the effort to replace the need for donor
pancreata for islet transplantation; however, these cells are not immune-protected. Therefore, in order
to capitalize on this virtually unlimited source of beta cells, it is necessary to develop methods for
immuno-protection. Several groups have postulated the use of inert biomaterials that could shield beta
cells from immune cells, while allowing for glucose-sensing and insulin secretion. Vegas et al. reported
successful application of polymeric encapsulation of human beta cells in diabetic, immune-competent
mice [130]. Although encapsulation methods protect beta cells from immune cells and allow normal
function, they still face several hurdles, including proximity to blood vessels and foreign body response
to biomaterial implantation. However, recent advances in genetic engineering and immunology
may lead to the generation of immune-privileged cells without the need for immunosuppression or
encapsulation [131,132].
5.6. Bladder
Much of the research on bladder whole organ engineering in the past couple decades have been
focused on developing decellularized, biomaterial, or composite scaffolds for bladder regeneration
in animal models [133–135]. These scaffolds can pose challenges due to the inability to effectively
control cellular remodeling of the graft, resulting in incomplete cellular infiltration, fibrotic scarring,
and infection of the graft, leading to a loss in function and even death in animal models [136]. This is
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why more recent approaches to bladder tissue engineering have focused on reconstructing the cellular
components of the bladder, primarily focusing on the urothelium and smooth muscle layers.
A phase II clinical trial conducted by Joseph et al., used bladder tissue biopsies from children
and adolescents with Spina Bifida to create an autologous bladder graft on a biodegradable PLGA
scaffold as an alternative to augmentation cystoplasty [137]. Patient-specific grafts were taken from
the bladder dome, and then urothelial cells and smooth muscle cells were cultured separately to form
layers that were then grafted onto the spherical PLGA scaffold [137]. This construct was then sutured
to the inside of the patient’s bladder to improve bladder capacity and compliance [137]. This approach
failed however due to a lack of bladder cycling after the operation, the limited proliferation capacity of
the cells taken from the biopsies in a diseased bladder, and possible expression of the disease phenotype
in the grafted cells taken from the diseased bladder [137]. Due to the limitations in proliferative
capacity and ease of access of adult bladder cells, pluripotent and adult stem cells have been explored
extensively as an alternative for autologous regenerative bladder grafts.
A study conducted by Zhe et al., used bladder acellular matrix grafts seeded with adipose-derived
stem cells in a rat model of bladder augmentation [138]. Compared to an unseeded control group,
the stem cell-seeded group had greater bladder capacity as well as greater regeneration of smooth
muscle and nerve cells [138]. This complete regeneration of tissue in adipose stem cell-seeded BAM’s
has significant advantages over using autologous cells from bladder biopsies. This is because harvesting
adipose tissue from a patient is less invasive than bladder tissue and adipose-derived mesenchymal
stem cells (ADMSC) are cheaper and easier to proliferate in culture than terminally differentiated
bladder cells. Additionally, ADMSCs are less likely to express a disease phenotype than cells derived
from a diseased bladder [138]. Overall, the advantages of using adipose-derived stem cells significantly
improves the potential for future clinical translation of Zhe et al.’s technique tested in rats, even
compared to other stem cell methods using human embryonic stem cells or bone marrow-derived
stem cells due to ethical concerns and the invasiveness of the procedure, respectively [138]. This study
has inspired several similar follow-up studies, including one by Moreno-Manzano et al., where human
ADMSCs were seeded on a decellularized rat bladder scaffold to regenerate a rat bladder after partial
cystectomy [139]. The seeded bladder scaffolds resulted in regeneration of urothelium, smooth muscles,
nerves, and even vasculature in the neo bladder to a much greater degree than non-seeded controls,
leading the authors to conclude that with further advancements, this technique could be effectively
applied to bladder transplantations in humans [139].
5.7. Skin
Engineered full-thickness skin grafts should ideally be developed with scaffolding representative
of the diverse structure in native epidermis, dermis, and subcutaneous fat, which, similar to other
organ engineering methods, has been accomplished using decellularization methods [66]. Using
perfusion decellularization of porcine full-thickness skin flaps, Jank et al., created a novel method for
generating an acellular skin flap scaffold in 2017 [66]. In vitro tests revealed that the decellularized
skin tissue maintained native mechanical properties and could be successfully reendothelialized after
perfusion with HUVECs [66]. The most notable results from Jank and colleagues were from their in vivo
studies, which found that their engineered skin underwent neovascularization and complete tissue
integration at greater rates than native xenogeneic skin or commercially available dermal substitutes
when implanted onto full-thickness skin defects [66]. Analysis of the immune cells that migrated to
the implant site revealed no evidence of rejection and only showed signs of inflammation associated
with the wound healing process, with the acellular scaffold promoting tissue regeneration without
signs of scarring [66]. The ability of Jank and colleagues’ graft to promote regeneration without scar
tissue forming is vital, as scar formation is a significant concern with full-thickness dermal injuries as it
can result in severe limitations in function and mobility of an individual.
Other strategies for skin tissue engineering involve the use of de novo ECM bioscaffolds
on which cells are seeded so that they can proliferate and generate ECM and tissue [140,141].
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Sander et al., utilized a biodegradable composite scaffold comprising collagen I and chondroitin-sulfate,
a component of cartilage [140]. The scaffolds were seeded with human dermal fibroblasts and then
epidermal keratinocytes, evaluating the engineered skin substitute with both in vitro and in vivo
studies with athymic mice [140]. The in vitro results demonstrated that mechanical properties of
Sander and colleagues’ skin substitute were dependent on the combination of materials and cell
types used [140]. When comparing the mechanical properties of engineered skin before and after
implantation, it was found that implantation was beneficial for the graft to develop more stable
mechanical properties that resembled native tissue, as the graft was remodeled by the host [140]. These
results were indicative of a viable skin substitute, as the ability of an engineered graft to be remodeled
is important for implant integration.
Bottom-up 3D bioprinting approaches have also been utilized in generating full-thickness tissue
constructs, particularly to control the placement of structures such as pores and vasculature for
the engineered tissue [142,143]. Baltazar et al. showed that 3D bioprinting could be used to generate a
construct with vasculature, in which several cell types could be cultured [142]. Similarly, Liu et al. used
the resolution and control with which bioprinted scaffolds can be generated to create a gelatin scaffold
loaded with ECM-components with precise placement of pores [143]. This allowed for the growth
of sweat glands within the construct in vitro [143]. The ability to precisely place and grow glandular
components of engineered skin is important in skin regeneration, as natural repair mechanisms fail to
do so when repairing full-thickness skin injuries.
5.8. Gastrointestinal
Similar to bladder whole organ engineering, many of the early approaches to engineering organs
of the gastrointestinal tract, including esophagus, stomach, small intestine, colon, and anal sphincter,
consisted of a biodegradable polymer, decellularized ECM, or composite scaffold designed to recruit
surrounding cells in order to regenerate the host tissue in rat and dog models [144,145]. These
approaches have seen successful in small animal models and small defect repair but may not be viable
for regenerating larger defects or entire organs as they rely purely on host cells to regenerate the tissue.
More recent approaches have also included intestinal organoids cultured in vitro from host cells
incorporated into full thickness scaffolds to increase the regenerative potential of these grafts in vivo,
which have shown some success in recovering organ function in rat models [146,147]. Grafts of this type,
however, only exhibited the most basic structural components of functional intestinal tissue and were
not evaluated for barrier function as well as digestive and adsorptive capabilities [148]. A more recent
study by Grant et al., sought to improve this model by generating intestinal organoids from human
and mouse intestinal mesenchymal stem cells and endothelial cells and seeding them onto the surface
of biodegradable polyglycolic acid tubes to create a tissue-engineered small intestine (TESI) [148,149].
The TESI constructs were then implanted into transgenic mice and evaluated 4 weeks later ex vivo [148].
The results of this study showed that TESI formed from both human and mouse intestinal stem
cells were shown to be highly similar to native tissue in both its ultrastructural components and its
secretory, digestive, and absorptive capabilities, indicating a high potential for clinical translation [148].
This technique of using mesenchymal stem cells to regenerate gastrointestinal tissue has been applied
to tissue engineering of the stomach in other studies, such as one conducted by Nakatsu et al., which
used bone marrow-derived mesenchymal stem cells (MSC) cultured on small intestinal submucosa
to patch artificial stomach defects in rats [150]. The presence of mesenchymal stem cells enhanced
the regeneration of smooth muscle in the SIS graft compared to an unseeded control, indicating that
mesenchymal stem cells have wide applicability in regeneration of hollow organs, especially in the GI
tract and bladder [150].
The esophagus is a similar tissue in the GI tract that is a focus of tissue engineering but presents
unique challenges as it has a much lower capacity for in vivo regeneration than the intestines
and stomach and has to have superior mechanical properties in order to function properly [151].
A recent and highly experimental technique developed by Kim et al., uses a composite polymer scaffold
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composed of an inner layer of electrospun polyurethane nanofibers and an outer layer of 3D-printed
polycaprolactone microfibers seeded with human adipose-derived mesenchymal stem cells [151].
The inner electrospun layer enhances cell migration by providing 3D topical cues and the outer layer
provides mechanical strength and flexibility to the construct [151]. The seeded constructs were then
either cultured in a perfusion bioreactor or transplanted into omental tissue and then used as a full
circumferential graft in a rat esophagus [151]. This technique resulted in the regeneration of the mucosa
and smooth muscle around the full circumference of the grafted construct, which is not achievable with
decellularized constructs alone; however, there were many complications associated with the surgical
implantation and mechanical properties of the scaffold, indicating the need for further research
on different polymers and natural biomaterials and the need to conduct large animal studies [151].
Despite the significant amount of research needed to bring these whole organ therapies to clinical
viability, one GI tract organ therapy that is extremely close to achieving this is tissue-engineered anal
sphincters for treating fecal incontinence (FI). A recent study published in Nature Scientific Reports by
Dadhich et al. created bioengineered anal sphincters using smooth muscle cells and neural progenitor
cells from gut biopsies that were seeded onto a ring-shaped collagen hydrogel [152]. The construct
formed an innervated ring of smooth muscle cells that when surgically implanted into a non-human
primate FI model, cured the condition within 3 to 4 weeks of the surgery [152].
Table 1. Summary of the most significant publications in the past decade.
Year Title Number of Citations Summary and Significance
2010
Preparation of Cardiac




In this study, a whole porcine decellularized heart
was obtained in less than ten hours using pulsatile
retrograde aortic perfusion of various enzymes,
detergents, and acid solutions. This decellularized
heart not only maintained the ECM components
and mechanical properties of a native heart but also
supported the differentiation of chicken
cardiomyocytes into sarcomeres. This study marked
the first full-scale decellularization of a heart close to
human proportions and paved the way to using
decellularized hearts in preclinical and clinical
studies for cardiac therapies. Additionally,
the perfusion method used for decellularization of
whole organs is superior to previous methods
in maintaining the native ECM compositions
and architecture and efficiently removing cells. As a
result, this method has been adapted for
decellularizing other organ types, advancing
the entire field of whole organ engineering as a result.
2011
The Use of Whole Organ
Decellularization for
the Generation of a Vascularized
Liver Organoid (Baptista) [63]
393
In this study, whole livers were engineered with
functional vasculature by first using perfusion
decellularization of detergents through the vascular
network of the liver followed by perfusion of human
fetal liver and endothelial cells through this vascular
network. This resulted in the creation of whole livers
in vitro seeded with human cells containing
vasculature with fully formed endothelium
and differentiated hepatic and epithelial tissues
surrounding them. This study represents a
significant advancement in whole organ engineering
since many approaches lack the creation of
functional vasculature, which is essential to support
cell viability and tissue function, and struggle to both
adequately decellularize large organs
and recellularize them with the appropriate number
of cells to create a functional engineered organ.
This method overcomes those challenges by using
the existing vascular network of the organ to both
remove the cells, recellularize the organ, and form a
new vascular network to support the organ.
The influence of this study on the field of whole
organ engineering is immense as it opens the door to
clinical translation of engineered whole organs for
organ repair and transplantation.
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2012
Decellularization Methods of
Porcine Kidneys for Whole




In this study, whole porcine kidneys were
decellularized with a high-throughput system that
pumped detergents through the renal vasculature.
The porcine cells were successfully cleared while
maintaining the complex microvasculature of
the kidneys as well as the native ECM structure
and composition. The decellularized kidneys were
then evaluated for cytotoxicity and the kidneys
perfused with 0.5% SDS showed no significant
difference in cell viability from tissue plastic controls.
The ability to efficiently and reproducibly
decellularize organs with complex microvasculature
like the kidney at a clinically relevant scale is a huge
step towards clinical translation of engineered whole
organs. Additionally, the low cytotoxicity
and maintenance of ECM composition
and morphology of this method allows for
the application of a number of different
recellularization strategies using pluripotent stem
cells, adult stem cells, and somatic cells. The ability
of this system to simultaneously decellularize 24
human-sized whole organs at once gives it
the production efficiency to meet the high unmet
demand for whole organ transplantation. Overall,
this study marks the first step towards mass




Pancreas as a Natural 3D
Scaffold for Pancreatic Tissue
and Whole Organ Engineering
(Goh) [124]
151
In this study, the unmet need for a regenerative
medicine therapy to address type I diabetes is
addressed by creating a decellularized
pancreas whole organ and reseeding it with
pancreatic cells. The pancreas was perfused with
0.5% SDS through the pancreatic vasculature to
remove the cellular components. These scaffolds
were successfully implanted in vivo without killing
surrounding cells or inducing the foreign body
response. The scaffolds were also seeded in vitro
with beta islet and acinar cells using retrograde
perfusion of the hepatic portal
vein and the pancreatic duct, respectively. Both cell
types maintained high viability and showed
appropriate localization in the scaffold during a
five-day culture period. Additionally, the beta cells
maintained insulin production capabilities
and the acinar cells maintained amylase production
over the entire culture period. This study is the first
successful attempt at creating a tissue-engineered
whole pancreas that produces insulin and provides a
unique opportunity for the millions of people
afflicted with type 1 diabetes. This treatment could
eventually replace insulin injections and pumps,
which are expensive and inconvenient, as a
treatment for type 1 diabetes by instead providing an
engineered whole organ transplant that would




Scaffold Using Embryonic Stem
Cells (Bonandrini) [154]
96
Though leveraging the native ECM structure
and biochemistry of cadaveric whole organs via
decellularization and recellularization is a promising
approach to engineering whole organs, one of its
limitations is the time needed to perfuse
and decellularize the organs. In this publication,
Bonandrini et al. presented an accelerated perfusion
decellularization protocol that was capable of using
an ionic detergent solution of SDS to decellularize rat
kidneys in just 17 h, with sufficient preservation of
native ECM for infused murine embryonic stem cells
to uniformly distribute, attach, and begin to
differentiate. This relatively short time to
decellularize rat kidneys is significant due to
the need for improved manufacturing efficiencies for
engineered whole organs to be clinically relevant.
However, this protocol is limited due to a lack of
replication in human-scale organs and its specificity
to kidneys. Different tissues require varying
decellularization protocols, and only using an SDS
as the decellularization solution may not translate to
other organs due to the documented harshness of
ionic detergents.
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In this study, rat and sheep livers were decellularized
through perfusion of either Triton X-100 + SDS or
SDS-only detergents and then recellularized either by
in vivo implantation into rats or in vitro through
perfusion of cell suspension media through
the hepatic vein of the decellularized constructs.
The results of the study showed that
decellularization using the Triton X-100 + SDS
detergent showed superior removal of cells,
maintenance of native ECM architecture,
and retention of mechanical properties relative to
native tissue. These decellularized whole organs
were successfully reseeded with hepatocytes in vivo
and in vitro. The in vitro reseeding resulted in a
native liver-like cellular architecture infiltrating both
the regions surrounding the vessels
and the parenchyma. This study represents a
significant advancement over previous de-cell-re-cell
studies of whole livers, which were only able to
recellularize the vasculature or areas immediately
surrounding the vasculature, whereas this study
developed a technique for decellularization that
enabled cellular infiltration throughout the entire
thickness of the construct. This is a major step
towards clinical viability of engineered whole organs
since many rely on perfusion recellularization
approaches but have had limited success with
seeding the entire organ due to the distorted
morphology of the ECM resulting from using an SDS







In this study, human hearts were decellularized
using perfusion-decellularization to obtain human
acellular cardiac scaffolds and whole heart scaffolds.
Scaffolds derived from 2D and 3D slices of acellular
human myocardium were seeded with iPSC derived
cardiomyocytes in static culture conditions
and formed contractile cardiac tissue after 4–7
and 7–10 days, respectively. Human whole heart
scaffolds were partially seeded with iPSC-derived
cardiomyocytes by injection into different regions of
the left ventricle followed by coronary artery
perfusion of media and left ventricle wall mechanical
stimulation in a custom bioreactor. The resulting
ventricle tissue showed 50% cellular repopulation
and maintained 90% cell viability over the culture
period. The tissue also demonstrated visible
contractile function when electrically stimulated
and produced measurable spontaneous contractions
and ventricular pressures of 2.4 mmHg. While
this study did not produce a fully functional
engineered heart, it is the closest anyone has come to
producing an engineered whole heart at the clinically
relevant scale. Additionally, this study used iPSCs to
recellularize the whole heart matrix, which can allow
for the creation of a patient-specific organ by
obtaining iPSCs from the transplant patients own
tissues. The ability to create a patient-specific organ
for an organ with such complexity and high
metabolic demands as the heart makes this study is a
major milestone in the field of whole organ
engineering. More work is needed to develop
this technique to produce engineered whole human
hearts that are clinically relevant for transplantation.
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In 2017, Kitano and colleagues published their
research on the successful engineering of intestinal
grafts populated with human iPSCs, which, after 28
days of culturing, demonstrated intestine-specific
functionality. Sections of intestine were perfusion
decellularized and then recellularized using
spheroids comprising human iPSCs, with these
spheroids adhering to the scaffold and forming a
functional epithelial barrier capable of transferring
nutrients across itself. These functional intestine
grafts were then implanted into mice, after which
the epithelial layer formed further matured
and continued to transfer glucose and fatty acid
nutrients. The functionalization of an implanted
engineered graft is highly promising; however,
this protocol is suited towards relatively simpler
organs comprised of thinner tissues and may not be
able to be translated for engineering more complex




Grafts on Porcine Matrix (Zhou)
[117]
28
In this study, human-scale tissue-engineered lungs
were created by perfusion decellularization of
porcine whole lungs with SDS followed by Triton
X-100. The vasculature of the lungs was then seeded
with HUVECs by perfusion of cell suspension media
through the pulmonary artery and vein. Epithelial
cells were seeded into the bronchi in media
suspension at a pressure of 80 mmHg followed by a
period of perfusion culture through the pulmonary
artery for 6 days to allow for endothelialization
and epithelialization of the decellularized lung
scaffold. The engineered lungs were then
transplanted into adult pigs and evaluated for
gas exchange and perfusion in vivo.
The tissue-engineered lungs not only developed
endothelialized vasculature and capillaries as well
as a complete epithelium in the bronchial tubes, but
the endothelial and epithelial cells rebuilt functional
alveoli in the decellularized ECM allowing for
gas exchange to occur. While the capacity for
gas exchange of the engineered lungs was about 50%
of that of the native lung in the porcine model,
this study is the first to successfully create a whole
bioartificial lung at a clinically relevant scale that
recapitulates the function of the native lung in vivo.
With further research, this technique could
potentially produce clinically relevant bioartificial
lungs for human transplant.
2019
Vascular Bioengineering of
Scaffolds Derived from Human
Discarded Transplant Kidneys




Leuning et al., demonstrated that focusing on
preservation of GAGs when decellularizing kidneys
can result in improved reendothelialization after
infusing the kidneys with cells. They found that
GAG preservation resulted in enhanced
reendothelialization when coupled with preloading
of growth factors, as the growth factors utilize GAGs
to exert their effects. In addition, they developed a
novel perfusion recellularization system that
simultaneously infused acellular kidney scaffolds via
the arteries and veins, which resulted in significantly
improved endothelial covering of the vasculature by
the infused endothelial cells derived from iPSCs.
The methods presented in this publication were
successfully used on both mouse and human
cadaveric kidneys. As adequate endothelialization is
vital for vasculature to function properly in organs,
Leuning and colleagues’ work is a notable
contribution to whole organ engineering. Their work
in retaining specific ECM components during
decellularization and developing a novel
recellularization method, if translatable to other
organs, would be a very useful protocol.
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2020
Fast, Robust and Effective
Decellularization of Whole





This study developed an improved technique for
perfusion decellularization that keeps a constant
pressure of 120 mmHg in the perfused detergent
solution and uses only TX-100 instead of SDS or a
combination of SDS and TX-100. The researchers first
conducted a preliminary study with porcine livers to
show the decellularization properties of different
detergent combinations when perfused through
the liver vasculature. The preliminary study showed
that while SDS is more effective at clearing cells from
the tissue, it is a harsh solvent and partially destroys
the ECM and GAGs of the livers in the process,
which makes it less effective as a biomimetic scaffold.
In contrast, the TX-100 does not damage the ECM
and GAGs but does not remove cells efficiently
enough in oscillating flow conditions.
The pressure-controlled TX-100-only method
overcame both of the issues with the previous
methods. The constant pressure enabled the TX-100
to more efficiently clear cells from the tissue, cutting
down the decellularization time to 20 h compared to
96 h for the oscillating flow TX-100 protocol,
and the use of TX-100-only preserved the ECM
and GAGs of the liver tissue. To prove
the effectiveness of this procedure, the human liver
tissue and whole porcine livers were perfusion
recellularized with hepatic cells and the resulting
engineered tissues/organs showed high cell viability
and significant cellular infiltration of the parenchyma.
This improved method for decellularization of whole
organs will improve the quality and resulting clinical
viability of future tissue-engineered whole organs
that utilize this method, not just liver.
6. Supporting Technological Advances
6.1. Cell Transplantation
Cell transplantation therapies for organ function restoration and tissue regeneration have
been developed utilizing adult cells, adult stem cells, and iPSCs [159–162]. Similar to organ
transplantation, adult cell transplantation has been used to substitute for a lack of native organ
function. The insulin-producing beta islet cells of the pancreas have been transplanted into patients
with type I diabetes and have been successful in maintaining blood sugar levels by releasing insulin into
the host after implantation [159,163]. The case of islet transplantation is unique in that islet cells make
up only about 2% of the pancreas but transplanted islets are still able to provide clinically relevant
levels of insulin without pancreatic tissue being transplanted as well [159]. Recognizing what part or
parts of an organ are most vital to its function, such as the islet cells for the pancreas, are critical for
engineering functional whole organs. Adult stem cells and iPSCs have both been used to regenerate
cells and damaged tissue via injection [160,161]. Stem cells are transplanted with the intention of
using the microenvironmental cues of the surrounding tissue to induce differentiation of the stem
cells into the same type of cell as the tissue they are injected in [164]. For instance, myoblasts have
been injected into a site of myocardial infarction in several animal models, with transplantation being
shown to improve the heart structure, tissue mechanics, and overall functioning [160]. The promising
results of stem cell transplantation for tissue regeneration provide valuable insight into the role that
the microenvironment of native ECM can have on cell functions and can be translated into growing
cells for whole organ engineering.
6.2. Immuno-Therapy
Modulating the immune response has been a core part of tissue transplantation. The inflammatory
response in particular is an issue for implanted materials, as inflammation can lead to biomaterial
encapsulation in fibrin [165]. In addition, host immune response becomes an even greater concern once
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cells are implemented in a bioscaffold, as non-autologous cells will present antigens to the host immune
system that will elicit an immune response [9]. Understanding how the immune system responds to
foreign materials and cells through the study of therapies to modulate the immune system has led
to the development of various materials that can mitigate the immune response that can be applied
to bioscaffolds and organ engineering [166]. Furthermore, immunotherapies have been developed
that engineer biomaterials to influence the adaptive immune system’s cells, namely the B and T cell
lymphocytes [166]. T lymphocytes typically differentiate into cytotoxic T cells to kill cells infected
with pathogens and B lymphocytes differentiate into antibody secreting cells. Both lymphocyte types
play a role in modulating macrophage phenotype and the implant/injury response pathways through
which new ECM materials are synthesized [166]. Biomaterials have been developed such that their
interactions with lymphocytes and macrophages promote a regenerative phenotype instead of a foreign
body response [166]. Leveraging this kind of immunomodulation in engineering bioscaffolds could be
highly conducive towards the integration of cells and tissue grown on the scaffold as well as integration
of the construct upon implantation.
6.3. Three-Dimensional Cell Cultures
Three-dimensional (3D) cell cultures are one of the key technologies that form the basis of whole
organ engineering. Cell morphology can greatly affect the cell’s functions, and 2D cultures can alter
a cell’s morphology from its native shape by a great extent. Cells extracted from tissue and placed
in a 2D culture become flat, can fail to divide, and lose their differentiated phenotype [167]. Cells that
have lost their native morphology and function after transfer to a 2D culture have been shown to
regain their native phenotype after placement in a 3D culture gel, further emphasizing the importance
of a dimensionally biomimetic cell scaffold [168]. This is because when compared to 2D cell cultures,
3D culture environments are more similar to in vivo environments for most tissues and are thus able
to produce more physiologically similar cell activity for most cell types [169]. One of the seminal
works in developing 3D cell culture environments and in demonstrating the merit of using ECM
molecules as the scaffold material of choice was work by Mina Bissell examining the effect of 3D gel
substrates on gene expression of cultured cells [170]. Her work, along with most early 3D cell culture
methods, utilized hydrogels with more basic compositions, such as collagen gels. However, as 3D cell
culture scaffolds were further developed, more structurally and compositionally advanced scaffolds
were generated, such as engineering scaffolds to have built-in porosity to assist in cell infiltration
and adhesion [11]. Three-dimensional cell cultures showed great promise in being able to better
replicate in vivo functions than 2D cultures, allowing for more accurate in vitro cell biology studies
and disease modelling, with this ability leading to 3D cell culture use in tissue engineering [11].
6.4. Stem Cell Technologies
Human pluripotent stem cells, whether created via derivation from an embryo or through
induced pluripotency, are capable of indefinite self-renewal and possess the ability to differentiate
into essentially all mature cell types, and as a result are highly attractive candidate cell sources for
engineering tissue [171,172]. Human embryonic stem cells (hESCs) are derived from the inner cell mass
of an embryo and have the intrinsic potential to differentiate into any type of cell because hESCs are
the progenitors of every cell in the human body. hESCs have been successfully differentiated in vitro
to become neural, cardiac, and pancreatic islet cells, among many others [171]. In addition to their
differentiation potential, hESCs are favorable for tissue engineering and particularly for whole organ
engineering because they can be cultured and expanded while in an undifferentiated, pluripotent
state for an indefinite period of time, and as such could be expanded to produce a quantity of cells on
the scale needed to seed organ sized tissue scaffolds before being differentiated into the functional
cells needed [173]. However, even though they can be expanded in culture while undifferentiated,
hESCs being derived from human embryos means the source is not very abundant and produces
additional ethical considerations. Also, since hESCs cannot be sourced autologously, any potential use
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involving implantation of hESCs would require genetic modification to avoid an immune response.
iPSCs are another form of hPSCs that address some of the drawbacks of hESCs, as iPSCs are sourced
autologously. When delivering certain transcription factors to human adult cells placed in hESC
culture conditions, the adult cells revert to a pluripotent state [174]. iPSCs are valuable in whole organ
engineering because they offer a patient-specific cell source that, depending on the cell type, can also
be abundantly sourced [175].
A patient-specific alternative to human pluripotent stem cells for whole organ engineering is
adult stem cells. These are partially differentiated stem cells, such as mesenchymal or hematopoietic
stem cells, derived from mature tissues that can differentiate into multiple different cell types and can
be used to reconstruct organs from patient biopsies. Human adipose-derived mesenchymal stem
cells were used to reconstruct bladders on decellularized ECM scaffolds in rat models to regenerate
smooth muscle and nerve [139], and they were also used in a biohybrid esophagus implanted
in rats to generate smooth muscle in a polycaprolactone and polyurethane tubular scaffold [151].
Adipose-derived mesenchymal stem cells (ADMSC) provide a unique advantage because they are
abundant in host tissues, they can be harvested non-invasively, and they can be easily proliferated
in culture to therapeutically appropriate levels [176]. ADMSCs have also been shown in some studies
to have an immunoregulatory effect on surrounding tissues, preventing immuno-rejection of tissue
grafts upon implantation in the host tissue [177]. Most importantly, ADMSCs can be differentiated into
a number of different cell lineages, including muscle, endothelial, bone, cartilage, fat, and even neural
tissue efficiently and reproducibly [178–180]. This makes ADMSCs suitable for engineering whole
organs comprising these cells, as ADMSCs can be easily sourced and proliferated into a population
large enough to seed an organ-sized construct and are patient-specific.
An important consideration in developing engineered organs that incorporate stem cells or stem
cell-derived cells is the tumorigenicity of pluripotent stem cells [178,181–184]. Both hESCs and iPSCs
have been observed to form tumors comprising tissue from all three germ layers, called teratomas.
This has most notably been demonstrated in stem cell therapies involving direct injection of pluripotent
stem cells into patient tissues, and iPSCs have been shown to be more tumorigenic than hESCs in vitro;
however, research has also shown iPSC-derived cells to be tumorigenic as well [181–186]. Different
whole organ engineering approaches that utilize perfusion recellularization of an acellular scaffold have
been developed constituting a variety of techniques and cells of different potency, ranging from iPSCs
and progenitor cells to terminally differentiated cells. Due to the risk of tumor formation, it is vital that
these inconsistent recellularization protocols be standardized for each organ type to eliminate the risk
of tumor formation in whole organs engineered using stem cells and their derivatives. As such, further
development of stem cell technologies, particularly those that aim to improve the efficiency and safety
of pluripotent stem cell differentiation, is a key component of advancing whole organ engineering.
6.5. Genetic Engineering
CRISPR-Cas-based technologies have gained prevalent use in genetic modification research
as a result of their accessible and versatile ability to alter, regulate, and visualize genomes, enabling
significant advancement in the field of whole organ engineering. CRISPR-Cas tools have been
successfully utilized to accelerate genetics-focused research development, being suitable tools for
improving understanding of the genetics of diseases and new organisms. Cas-based biotechnology is
developing rapidly, to the extent that there are several clinical trials, both in progress or beginning
soon, that depend on Cas9 technology, and the results of which will likely determine how somatic cell
editing is used both in research and clinical applications in patients.
Human pluripotent stem cells such as iPSCs have strong potential in regenerative medicine
applications. Despite this potential, applications are limited by the risk of immune rejection arising
from an HLA mismatch. Cas9 techniques such as B2M gene knockout or HLA-homozygous iPSC stocks
have the potential to address immuno-compatibility concerns, however B2M knockout runs the risk of
eliciting natural killer (NK) cell activity and failing to present antigens, and for HLA-homozygous iPSC
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stocks, it can be difficult to recruit the rare donors needed. Xu and colleagues have developed two
approaches for gene editing of iPSCs to make them immuno-compatible [187]. The first is a method of
generating HLA pseudo-homozygous iPSCs by using allele-specific editing to genetically modify HLA
heterozygous iPSCs. The second method involves disrupting both HLA-A and HLA-B alleles as a means
of suppressing the NK cell response while still retaining antigen-presenting capabilities, producing
HLA-C retaining iPSCs as a result. This is valuable because iPSCs that retain HLA-C have been shown
to evade T cells and NK cells, both in vitro and in vivo. It is estimated that at least 90% of the human
population could be compatible with cells produced by combining 12 lines of HLA-C-retained iPSCs
with HLA-class II, which greatly facilitates iPSC-based regenerative medicine applications.
7. Major Challenges and Barriers to Market
7.1. Incorporation into Host Tissue
Vascular regeneration and innervation potential are essential for fully functioning transplants,
and are the most important among the technical challenges outlined in Figure 4 for achieving integration
into host tissue. An ongoing obstacle in establishing angiogenesis within engineered tissue constructs is
developing a way to provide sufficient vascularization for tissues with volumes greater than 2–3 mm3.
Without such vascularization built-in to tissue constructs, necrosis will occur before ingrowth of
host blood vessels can occur. Although some organs and tissues can successfully be manufactured
and transplanted without engineered vasculature, as shown by Elliot et al. in 2012 when they were able
to transplant bioengineered tracheas [188], it is clear that a functional vascular network is a prerequisite
for generating more complex organs.
Figure 4. Major challenges to clinical implementation and commercialization of engineered
whole organs.
A newer branch of angiogenic tissue engineering incorporates the formation of the lymphatic
system in bioengineered tissues and organs. As is the case with angiogenesis, lymphatogenesis
in engineered whole organs requires the control of tissue growth and the prevention of metastatic
behavior [189,190]. Incorporation of a construct into host tissue also requires innervation, and while
controlled axonal growth has been demonstrated in tissue engineering research [191], methods for
controlling the innervation of tissue constructs must be improved. While autologous peripheral
nerve grafts derived from the epineurium or sural nerve are the conventional treatment standards
for regenerating peripheral nerve injuries, autografts are limited by: limit of supply, the possibility of
creating wound pain, and the risk of causing lasting motor function reduction [192,193]. Innervating
an organ requires matching the mechanical properties of the graft with that of the surrounding tissue
of the implant site to facilitate diffusion and produce the appropriate degradation profile for when
nerve regeneration begins and axon recruitment from nearby nerves occurs [191,193].
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7.2. Achieving Sufficient Organ Function Post-Implantation
Sufficient parenchymal cells are required to integrate and repair new organs. In porous scaffolds,
it can be difficult to generate a homogeneous cell distribution, and often times cells that are seeded
onto a scaffold will remain on the outlying surface of the construct, resulting in a thin peripheral layer
of cells forming instead of a homogeneous infiltration of cells. In addition, controlled distribution
of incorporated cells cannot be achieved when dealing with multiple cell types. This severely limits
the creation of larger scale organs in more complex systems such as liver, lung, and kidney [194].
Additionally, in decellularized organ scaffolds, cell infiltration is even harder to achieve due to an
insufficient number of pores in the scaffolds. Decellularized scaffolds have lower potential for cell
infiltration as organs proceed towards adult stages of development [195].
7.3. Cost of Large-Scale Manufacturing
Adequately recellularizing organ-sized constructs such as the liver or heart with enough cells
to replicate native organ functionality will require billions of cells [196,197]. For instance, clinically
relevant contractile function in an engineered whole heart would require a quantity of cells on the scale
of the 2–3 billion cardiac muscle cells found in the native heart, and even then that is less than a third
of the number of total cells in the heart [197]. In addition to the cost of the cell and relevant culturing
equipment, large-scale manufacturing of tissue using conventional tissue engineering techniques would
require a large number of personnel that would need to be trained in cell culture techniques, requiring
time and money. An approach that may be able to improve upon conventional tissue culture methods
and expand them to large-scale manufacturing is the use of advanced robotics in manufacturing.
Not only could robotic manufacturing produce a larger scale of cells without the need for training
personnel, but fabrication could be performed in a closed system, reducing the risk of contamination
and thus further saving costs by mitigating the need to discard contaminated cells. In addition,
using machine learning algorithms and imaging techniques, manufacturing robots could be trained
to identify cells in a culture that have successfully undergone genetic modification or differentiation
and then isolate them for expansion, improving the efficiency of stem cell-derived cells for tissue
engineering. However, implementing novel manufacturing approaches in engineered tissues would
require extensive regulations for developing protocols and investigating the safety of the process.
A majority of the published preclinical research studies involving decellularization
and recellularization have been unable to establish the cell numbers needed to restore original
organ function. Uygun et al., were able to recellularize a liver with roughly 5–20% of the original
native hepatic mass in their preclinical animal model [40]. Park et al. were able to repopulate a
decellularized rat liver with roughly 20 million iPSCs, which were able to differentiate into hepatic
cells [198]. However, this only corresponds to less than 5% of the whole rat hepatocyte cell count.
The cost of these studies were thousands of dollars. In order to make whole organ engineering, these
numbers would have to be scaled to orders of magnitude higher, which would be extremely expensive.
In order to decrease contamination and improve functionality, more money would have to be spent on
improving quality control metrics.
7.4. Regulatory Approval
A unique challenge confronting the development of engineered tissues and organs not encountered
in the use of donor organs is the administrative policies that must be satisfied. In the US, the Health
Resources Service Administration regulates the National Organ Transplant Program. However,
engineered whole organs fall under the category of HCT/Ps (human cells, tissue, and cellular
and tissue-based products), and are regulated by the FDA via the Center for Biologics Evaluation
and Research (CBER) and under Title 21 of the Code of Federal Regulations (CFR) [199]. Parts 1270
and 1271 of Title 21 specifically outline the rules and practices that must be adhered to when implanting
or infusing HCT/Ps, including policies for screening and testing the tissue sources [200].
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Furthermore, because of the novel and untried nature of engineered whole organs in humans,
any engineered organ developed would be subject to Premarket Approval (PMA) regulations according
to part 814 of Title 21 before being eligible for establishment as a medical product [199,200]. Parts 1270
and 1271 of Title 21 specifically outline the rules and practices that must be adhered to when implanting
or infusing HCT/Ps, including policies for screening and testing the tissue sources [200].
An engineered whole organ would be considered a Class III device under PMA guidelines, which
is the most stringently regulated device type. This is understandable as Class III devices are those that
will be used to sustain human life or prevent substantial impairment of health and are devices with
the highest risks associated with their use [199,201].
A PMA application must demonstrate safety and effectiveness of the proposed device via
non-clinical laboratory testing in compliance with part 58 of CFR Title 21, with these non-clinical
studies demonstrating enough merit for the device to safely advance to clinical investigations to show
safety and effectiveness in humans, which must also be included in the PMA application. It is crucial
to maintain ethical protocols and patient safety when beginning clinical studies for a Class III PMA.
Though there are study protocols that can be adapted from previous clinical studies using allogenic
transplants and synthetic implants, the novel and high-risk nature of implanting engineered whole
organs means that new, stringent approaches for assessing the safety of engineered whole organs
in preclinical and clinical studies will need to be developed.
Further administrative challenges will need to be dealt with for any whole organ device that
receives PMA. A novel device such as an engineered whole organ will likely be unviable in the medical
device market if insurance companies do not reimburse costs for implementing it. Because of this, a
new medical device will benefit from being developed to benefit not only patients but also insurance
companies, i.e., be cost effective. As such, preclinical and clinical tests of an engineered whole
organ should be done to demonstrate the device’s safety, efficacy, and capacity to perform without
costly downsides of current methods of treating end-stage organ disease. For engineered whole
organs, this condition could potentially be achieved largely due to the fact that the organs will use
patient-specific cells, eliminating insurance costs associated with allogenic transplants (e.g., medication
for patients on a transplant waitlist, medication after transplant surgery to mitigate transplant rejection,
and potential subsequent surgery if transplant rejection does occur). However, while engineered whole
organs have some potential advantages over allogenic organ transplants in terms of economic costs,
there is also a potential downside. Namely, the process of engineering whole organs is expensive,
as specific cell culture and tissue engineering materials, methods, and training are needed in most,
if not all, whole organ engineering approaches.
Additionally, while patient specificity is one of the main attractive features of whole organ
engineering, it also further increases the economic cost of engineering a whole organ, as traditional
manufacturing methods are not suited for adaptation to large-scale, low-cost manufacturing of custom
organs. A potential solution to this problem lies in the field of advanced robotics, wherein complex
and precise machines can perform tissue engineering procedures autonomously via machine learning
algorithms, potentially increasing both the scale and efficiency of whole organ engineering. Of course,
regulatory concerns must be considered in order to implement such novel manufacturing technology.
8. Conclusions
There has been significant interest in the fields of whole organ engineering, tissue engineering,
and regenerative medicine over the past few decades. This has been especially true because of the fact
that end-stage organ failure continues to be a leading cause of morbidity and mortality around the world.
Orthotopic organ transplantation is currently the only curative treatment option available for patients
diagnosed with end-stage organ failure. However, significant advances in bioengineering of whole
organ constructions continue to advance at a rapid pace, giving hope to those awaiting transplantation.
Whole organ engineering has been supported by key technological advancements over the past
few decades. These include (1) methods of whole organ decellularization and recellularization,
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(2) three-dimensional bioprinting, (3) advanced stem cell technologies, and (4) the ability to genetically
modify tissues and cells. These advancements give hope that organ engineering will become a
commercial reality in the next decade. However, several barriers to commercialization are still
major obstacles that need to be systematically addressed. Engineering whole organ constructs with
adequate cell populations is a significant technical barrier, as it is currently highly challenging to
create an engineered organ with a homogenous cell density close to the high cell density that native
organs possess. To address this barrier, stem cell research must be developed to improve cell invasion
and adhesion of organ constructs. In addition to improving density of cells incorporated into engineered
whole organs, the diversity of cells used must also be improved to better mimic the cell diversity found
in native organ tissue. Though whole organ de-cell/re-cell approaches and cell bioprinting approaches
have demonstrated the ability to incorporate multiple cell types into engineered organ constructs,
this is often for the purpose of replicating but a single part of an organ’s function, rather than replicating
the entirety of the organ’s functions. Also, though the variety of approaches to stem cell culture
and differentiation, whole organ recellularization and decellularization, bioprinting, and genetic
modification techniques being developed is conducive for research purposes, standardization is
vital for clinical implementation of these techniques. Standardization necessitates the comparison of
various methods in comprehensive studies for identifying the safest and most effective approaches
to engineering whole organs, as demonstrated by multiple studies performed by different research
groups. As the ultimate goal of whole organ engineering is clinical translation and transplantation,
these standardized protocols would have to undergo strict regulatory examination.
Regulatory pathways are an additional challenge facing the utilization of engineered whole organs
as viable transplants and are principal among the non-technical barriers to commercial implementation.
This is an important challenge, as regulatory pathways ensure that novel medical technologies can
only be used commercially if they can properly demonstrate safety, with all potential risks and their
respective likelihood of occurring being documented. An additional challenge outside of developing
transplantable whole organ technology is the manufacturing of said organ. Current approaches for
engineering whole organs are very involved processes with low production volumes and no indication
of the ability to maintain consistent quality on a commercial scale. As a result, current methods of whole
organ engineering would not be able to make a difference in reducing the number of individuals that
die from end-stage organ failure. As such, it is necessary to develop novel manufacturing techniques
in parallel with ongoing whole organ engineering research.
Despite the field of whole organ engineering being quite new, much attention in research has been
focused on it and relevant technologies, such as stem cells developed with the goal of advancing
whole organ engineering. Though there are many barriers to the clinical implementation of engineered
organs, the critical need for a replacement for allogeneic organ transplantation makes whole organ
engineering research vital in overcoming these barriers.
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